Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# EGFR Lung Cancer Resisters

United with the goal of finding a cure for EGFR driven lung cancer

## Sitemaps

- [XML Sitemap](https://egfrcancer.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC](https://egfrcancer.org/2026/06/25/fda-grants-fast-track-designation-to-avzo-1418-db-1418-for-egfr-tki-pretreated-nsclc/) - AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.
- [NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease](https://egfrcancer.org/2026/06/25/nccn-releases-nsclc-guideline-update-dato-dxd-designated-as-a-preferred-second-line-regimen-in-egfr-mutated-disease/) - On November 6, 2025, The National Comprehensive Cancer Network (NCCN) released their updated Clinical Practice Guidelines in Oncology for NSCLC.
- [Early Data Suggest Primary Tumor Resection Following EGFR TKI Treatment May Help Delay Disease Progression in Metastatic NSCLC](https://egfrcancer.org/2026/06/25/early-data-suggest-primary-tumor-resection-following-egfr-tki-treatment-may-help-delay-disease-progression-in-metastatic-nsclc/) - PTR-1 trial results showed a higher pathological complete response for exon 19 deletions and greater survival benefit from the intervention for L858R mutations.
- [The Power of Community: Jill Feldman Shares Advice for Getting Involved in Lung Cancer Advocacy](https://egfrcancer.org/2026/06/25/the-power-of-community-jill-feldman-shares-advice-for-getting-involved-in-lung-cancer-advocacy/) - Jill Feldman, a patient advocate with lung cancer and co-founder of the EGFR Resisters, joined Lung Cancers Today to discuss her journey into lung cancer advocacy, provide advice for those who are interested in getting involved, and reflect on the power of finding community.
- [The New Face of Lung Cancer: A Conversation with Two Young Lung Cancer Warriors](https://egfrcancer.org/2026/06/25/the-new-face-of-lung-cancer-a-conversation-with-two-young-lung-cancer-warriors/) - Dr. Narjust Florez speaks with two remarkable young lung cancer advocates who are redefining what it means to live with the disease.
- [New EGFR Resisters/LUNGevity Research Project Funded: Local CAR T as a Novel Therapeutic Strategy for CNS Progression in NSCLC](https://egfrcancer.org/2026/06/25/new-egfr-resisters-lungevity-research-project-funded-local-car-t-as-a-novel-therapeutic-strategy-for-cns-progression-in-nsclc/) - This innovative CAR T research project brings hope for better, more effective CNS treatments.
- [Inaugural EGFR Resisters Patient and Caregiver Summit Was Awesome!](https://egfrcancer.org/2026/06/24/inaugural-egfr-resisters-patient-and-caregiver-summit-was-awesome/) - This past November, more than 110 patients and caregivers impacted by EGFR‑positive lung cancer gathered in Chicago for our first‑ever Patient & Caregiver Summit.
- [Lung Cancer in Nonsmoking Individuals](https://egfrcancer.org/2026/06/23/lung-cancer-in-nonsmoking-individuals/) - Lung cancer in nonsmoking individuals (defined as people who have smoked fewer than 100 cigarettes in their lifetime accounts for 15% to 20% of all lung cancer cases worldwide.
- [SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025](https://egfrcancer.org/2026/06/23/systimmune-inc-and-bristol-myers-squibb-announce-first-global-phase-i-results-of-iza-bren-an-egfr-x-her3-bispecific-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors-at-esmo-2025/) - SystImmune Inc. and Bristol Myers Squibb announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025
- [NorthStar: LCT Plus Osimertinib Boosts PFS in Metastatic EGFR+ NSCLC](https://egfrcancer.org/2026/06/23/northstar-lct-plus-osimertinib-boosts-pfs-in-metastatic-egfr-nsclc/) - Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.
- [Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease](https://egfrcancer.org/2026/06/23/zipalertinib-shows-early-efficacy-with-manageable-safety-in-egfr-mutant-nsclc-with-cns-or-leptomeningeal-disease/) - Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.
- [Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC](https://egfrcancer.org/2026/06/23/second-line-sacituzumab-tirumotecan-displays-pfs-benefit-in-egfr-nsclc/) - Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.
- [ESMO 2025: Latest in EGFR mutant NSCLC](https://egfrcancer.org/2026/06/23/esmo-2025-latest-in-egfr-mutant-nsclc/) - In this video, Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom, and Prof Pascale Tomasini discuss the latest advances in EGFR+ NSCLC.
- [Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study](https://egfrcancer.org/2026/06/23/phase-ii-study-of-lazertinib-and-pemetrexed-in-patients-with-epidermal-growth-factor-receptor-mutation-positive-non-small-cell-lung-cancer-and-leptomeningeal-metastases-the-kcsg-lu-21-01-lazarus-stu/) - This study evaluated the efficacy and safety of lazertinib plus pemetrexed in patients with EGFR-mutant NSCLC and leptomeningeal disease.
- [BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643](https://egfrcancer.org/2026/06/23/blossomhill-therapeutics-presents-preliminary-findings-from-phase-1-2-solara-trial-of-bh-30643/) - BH-30643 demonstrates preliminary anti-tumor activity across a variety of advanced EGFR-mutant NSCLC lung cancers with complex and difficult-to-treat resistance mutations.
- [When EGFR+ Lung Cancer Spreads to the Brain](https://egfrcancer.org/2026/06/23/when-egfr-lung-cancer-spreads-to-the-brain/) - Drs Laura Alder (thoracic oncologist) and Trey Mullikin (oncology radiologist) lead a comprehensive discussion regarding the identification and treatment for brain mets and leptomeningeal disease.
- [Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases](https://egfrcancer.org/2026/06/23/identifying-the-genomic-landscape-of-egfr-mutant-lung-cancers-with-central-nervous-system-metastases/) - The genomic drivers of CNS dissemination are poorly understood in EGFR+ NSCLC
- [Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial](https://egfrcancer.org/2026/06/23/lazertinib-for-patients-with-nsclc-harboring-uncommon-egfr-mutations-a-phase-ii-multicenter-trial/) - This study investigated the efficacy and safety of lazertinib in patients with NSCLC with uncommon EGFR mutations.
- [Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in NSCLC treated with third-generation EGFR-TKIs](https://egfrcancer.org/2026/06/23/prognostic-implications-of-uncommon-egfr-exon-19-deletion-insertion-mutations-in-nsclc-treated-with-third-generation-egfr-tkis/) - This study evaluated the survival outcomes of patients with advanced NSCLC harboring EGFR exon 19 deletion-insertion (19delins) to 3rd-generation EGFR-TKIs administered as first- or second-line therapy.
- [WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos](https://egfrcancer.org/2026/06/23/wclc-2025-highlights-flaura2-harmoni-alchemist-with-dr-balazs-halmos/) - Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, discusses three pivotal studies that are shaping the future of lung cancer treatment.
- [Aumolertinib Plus Chemo Shows Modest PFS Gain Over Monotherapy for EGFR/TSG-Mutant NSCLC](https://egfrcancer.org/2026/03/26/aumolertinib-plus-chemo-shows-modest-pfs-gain-over-monotherapy-for-egfr-tsg-mutant-nsclc/) - Investigator Dr. Jie Wang presented results from the first-of-its-kind trial comparing combination therapy with monotherapy in this patient population.
- [AstraZeneca's 2025 Global Lung Cancer Advocacy Exchange](https://egfrcancer.org/2026/03/26/astrazenecas-2025-global-lung-cancer-advocacy-exchange/) - This slide deck is full of global lung cancer data from AstraZeneca's 2025 WCLC Advocacy Exchange: lung cancer funding trends, healthcare access and inequities, etc.
- [“Milestone” in EGFR-Positive NSCLC: The Importance of Options for Patient-Centered Care](https://egfrcancer.org/2026/03/26/milestone-in-egfr-positive-nsclc-the-importance-of-options-for-patient-centered-care/) - Experts talk about the FLAURA2 and HARMONi data presented at the World Conference on Lung Cancer and what the findings mean for patients with EGFR+ NSCLC.
- [How to Read & Write Conference Abstracts](https://egfrcancer.org/2026/03/26/how-to-read-write-conference-abstracts/) - Guidance on various aspects of research abstracts, from their purpose and structure to reviewing and writing effective abstracts that incorporate patient perspectives.
- [FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer](https://egfrcancer.org/2026/03/24/fda-approval-of-datopotamab-deruxtecan-dato-dxd-in-egfr-mutated-lung-cancer/) - The Oncology Brothers discuss the recent FDA approval of datopotamab deruxtecan (Dato-DXd) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC).
- [Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches](https://egfrcancer.org/2026/03/24/histological-transformation-in-lung-cancer-mechanisms-clinical-characteristics-and-therapeutic-approaches/) - Lung cancer exhibits remarkable histological plasticity, with NSCLC frequently transforming into SCLC as a resistance mechanism to targeted therapies and immunotherapies.
- [Highlights From ASCO 2025: Treatment Regimens for EGFR-Mutated Advanced NSCLC](https://egfrcancer.org/2026/03/24/highlights-from-asco-2025-treatment-regimens-for-egfr-mutated-advanced-nsclc/) - Dr Rotow discusses the results of multiple studies from ASCO 2025 that focused on treatment strategies for patients with EGFR-mutant advanced NSCLC.
- [FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations](https://egfrcancer.org/2026/03/24/fda-grants-accelerated-approval-to-zongertinib-for-nonsquamous-nsclc-with-her2-tkd-mutations/) - The FDA granted accelerated approval to zongertinib for pretreated, unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.
- [Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis](https://egfrcancer.org/2026/03/24/local-cranial-radiation-combined-with-third-generation-tyrosine-kinase-inhibitors-improve-leptomeningeal-metastasis-disease-free-survival-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-and-b/) - This study investigates whether LCR combined with 3rd-generation TKIs can influence the occurrence of LM in EGFR-mutated NSCLC with BM..
- [BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature](https://egfrcancer.org/2026/03/24/braf-fusion-as-resistance-mechanism-to-osimertinib-in-egfr-mutated-nsclc-a-case-report-and-review-of-literature/) - BRAF mutations and fusions are reported in 1% to 3% of patients with EGFR-mutated NSCLC receiving osimertinib and represent potential targetable alterations.
- [ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC](https://egfrcancer.org/2026/03/24/adc-bispecific-antibody-based-therapies-help-build-a-new-treatment-paradigm-in-egfr-nsclc/) - Sandip P. Patel, MD, discusses targeted therapy combination regimens in EGFR-mutated NSCLC.
- [Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC](https://egfrcancer.org/2026/03/24/frontline-iza-bren-plus-osimertinib-elicits-100-orr-in-egfr-mutant-nsclc/) - First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.
- [Tribute to Bonnie Addario](https://egfrcancer.org/2026/03/24/member-spotlight-andrew-kasten-2/) - Breathe easy Bonnie, we will carry on with the strength in purpose you demonstrated by believing in us.
- [“What I Tell My Patients:” Making Sense of New Treatment Options in EGFR-positive NSCLC](https://egfrcancer.org/2026/03/12/what-i-tell-my-patients-making-sense-of-new-treatment-options-in-egfr-positive-nsclc/) - In this episode of LungCancerRx, Drs. Eric Singhi, Aakash Desai, Fawzi F. Abu Rous, and Christine M. Lovly discuss the complexities of treating advanced EGFR-positive non-small cell lung cancer.
- [The Phase 3 HARMONi Trial: Dr. Le Shares Insights at IASLC WCLC](https://egfrcancer.org/2026/03/11/phase-3-harmoni-trial-dr-le-wclc/) - Xiuning Le, MD, PhD, of MD Anderson Cancer Center, joined Lung Cancers Today at IASLC 2025 World Conference on Lung Cancer to discuss an update on the HARMONi study.
- [WCLC 2025 Highlights: FLAURA2 trial](https://egfrcancer.org/2026/03/11/wclc-2025-highlights-flaura2-trial/) - At the WCLC 2025 Presidential Symposium Dr. David Planchard presented the Overall Survival (OS) results from the FLAURA2 trial.
- [COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC](https://egfrcancer.org/2026/03/11/compel-study-osimertinib-treatment-egfr/) - A new analysis from the COMPEL trial shared at the IASLC WCLC in September 2025.
- [American Cancer Society Lung Cancer Roundtable Webinars](https://egfrcancer.org/2026/02/20/the-mystery-rise-of-lung-cancer-in-non-smokers-2/) - A collection of webinars from the American Cancer Society Roundtable on various topics of lung cancer: staging, treatments, radiation, surgery, advocacy, etc
- [FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC](https://egfrcancer.org/2026/02/20/fda-grants-breakthrough-therapy-designation-to-izalontamab-brengitecan-in-egfr-nsclc/) - Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.
- [The mystery rise of lung cancer in non-smokers](https://egfrcancer.org/2025/11/21/the-mystery-rise-of-lung-cancer-in-non-smokers/) - The number of lung cancer cases in people who have never smoked is increasing.
- [Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma](https://egfrcancer.org/2025/11/20/combination-therapy-with-met-tyrosine-kinase-inhibitor-and-egfr-tyrosine-kinase-inhibitor-in-patients-with-met-overexpressed-egfr-mutant-lung-adenocarcinoma/) - This retrospective cohort study included patients with advanced EGFR-mutant LUAD who progressed after EGFR TKIs and were treated with combination therapy of EGFR TKIs and MET TKIs (capmatinib or tepotinib).
- [Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasis](https://egfrcancer.org/2025/11/20/efficacy-evaluation-of-tyrosine-kinase-inhibitors-for-advanced-non-small-cell-lung-cancer-patients-with-leptomeningeal-metastasis/) - Targeted therapies have demonstrated promising results in LM patients from advanced NSCLC, particularly in those receiving concurrent local leptomeningeal therapy.
- [First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC](https://egfrcancer.org/2025/11/20/first-line-osimertinib-plus-chemo-boosts-os-in-egfr-nsclc/) - Osimertinib plus chemotherapy improved overall survival in the first-line treatment of advanced non–small cell lung cancer harboring EGFR mutations.
- [FDA Grants Fast Track Designation to Next-Generation HER3-Directed ADC for EGFR+ Advanced NSCLC](https://egfrcancer.org/2025/11/20/fda-grants-fast-track-designation-to-next-generation-her3-directed-adc-for-egfr-advanced-nsclc/) - The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.
- [Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC](https://egfrcancer.org/2025/11/20/understanding-underlying-resistance-mechanisms-is-vital-for-guiding-treatment-selection-post-osimertinib-in-egfr-nsclc/) - Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.
- [Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report](https://egfrcancer.org/2025/11/19/combination-of-lurbinectedin-and-osimertinib-for-treatment-of-egfr-mutated-transformed-sclc-a-brief-report/) - In this case series, we report our experience of using lurbinectedin with osimertinib for the treatment of transformed SCLC.
- [Strategic Advances in EGFR+ NSCLC: Navigating Evolving Treatment Paths With Dato-DXd](https://egfrcancer.org/2025/11/20/strategic-advances-in-egfr-nsclc-navigating-evolving-treatment-paths-with-dato-dxd/) - Jacob Sands, MD, discusses the integration of datopotamab deruxtecan (Dato-DXd; Datroway) into the treatment landscape for EGFR+ NSCLC.
- [Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management](https://egfrcancer.org/2025/11/20/personalized-care-for-patients-with-egfr-mutant-nonsmall-cell-lung-cancer-navigating-early-to-advanced-disease-management/) - A comprehensive overview of the current landscape of EGFR+ NSCLC, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.
- [How To Access More Expert Opinions On Your Treatment Plan: The Molecular Tumor Board](https://egfrcancer.org/2025/11/20/how-to-access-more-expert-opinions-on-your-treatment-plan-the-molecular-tumor-board/) - The benefits of a molecular tumor board when you have cancer.
- [Empowered Choices: “The Most Important Conversations” Oncologists Can Have With NSCLC Patients](https://egfrcancer.org/2025/11/20/empowered-choices-the-most-important-conversations-oncologists-can-have-with-nsclc-patients/) - In this video, EGFR Resisters co-founder Jill Feldman discusses how physicians can better empower patients when making difficult therapy choices.
- [MEMBER SPOTLIGHT:  Andrew Kasten](https://egfrcancer.org/2025/11/20/member-spotlight-andrew-kasten/) - Andrew Kasten’s introduction to lung cancer started late in the afternoon on April Fools Day 2022.
- [AACR 2025: Redefining Cancer Survivorship for People Living with Advanced and Metastatic Cancers](https://egfrcancer.org/2025/11/20/aacr-2025-redefining-cancer-survivorship-for-people-living-with-advanced-and-metastatic-cancers/) - In this Major Symposium presented at the AACR Annual Meeting 2025, we explore the physical, emotional, and psychosocial aspects of survivorship among cancer patients.
- [Studies Find Supportive Care Approaches for Amivantamab in Lung Cancer](https://egfrcancer.org/2025/11/19/studies-find-supportive-care-approaches-for-amivantamab-in-lung-cancer/) - During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash with amivantamab in EGFR-mutated lung cancer.
- [Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors](https://egfrcancer.org/2025/11/19/genomic-profiling-and-prognostic-factors-of-leptomeningeal-metastasis-in-egfr-mutant-nsclc-after-resistant-to-third-generation-egfr-tyrosine-kinase-inhibitors/) - This study aimed to analyze the genomic profiling and prognostic factors of EGFR-mutant NSCLC-LM after resistance to third-generation EGFR-TKIs.
- [EGFR Mutation-Positive NSCLC: Fourth Annual National General Medical Oncology Summit](https://egfrcancer.org/2025/11/19/egfr-mutation-positive-nsclc-fourth-annual-national-general-medical-oncology-summit/) - Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.
- [Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States](https://egfrcancer.org/2025/11/19/overall-survival-in-egfr-mutant-advanced-nsclc-treated-with-first-line-osimertinib-a-cohort-study-integrating-clinical-and-biomarker-data-in-the-united-states/) - We used longitudinal U.S. medical oncology databases to evaluate real-world overall survival (rwOS) and prognostic risk factor groups in advanced EGFRm NSCLC treated with first-line osimertinib.
- [Virtual Tumor Board: Targeting Residual Disease](https://egfrcancer.org/2025/11/19/virtual-tumor-board-targeting-residual-disease/) - In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and Dr. David Carbone.
- [Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multi-center trial](https://egfrcancer.org/2025/11/19/lazertinib-for-patients-with-nsclc-harboring-uncommon-egfr-mutations-a-phase-ii-multi-center-trial/) - This study investigated the efficacy and safety of lazertinib in patients with NSCLC with uncommon EGFR mutations.
- [Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC](https://egfrcancer.org/2025/11/19/results-from-the-aeneas2-trial-point-to-a-new-frontline-treatment-option-for-nsclc/) - Research team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting.
- [FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression](https://egfrcancer.org/2025/11/19/fda-grants-accelerated-approval-to-telisotuzumab-vedotin-in-pretreated-advanced-nsclc-with-c-met-overexpression/) - The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.
- [HARMONI Trial: Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study](https://egfrcancer.org/2025/11/19/harmoni-trial-ivonescimab-plus-chemotherapy-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-egfr-mutant-non-small-cell-lung/) - Summit Therapeutics announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab.
- [Zipalertinib Offers Promising Oral Option for EGFR Exon 20+ NSCLC](https://egfrcancer.org/2025/11/19/raffaele-califano-md-on-egfr-mutant-advanced-nsclc-mariposa-2-2/) - For patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, the treatment landscape is poised for a significant shift.
- [Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2](https://egfrcancer.org/2025/11/19/raffaele-califano-md-on-egfr-mutant-advanced-nsclc-mariposa-2/) - Raffaele Califano, MD, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2 ( (Abstract 8639) at ASCO 2025
- [Patritumab Deruxtecan Falls Short in EGFRm NSCLC](https://egfrcancer.org/2025/11/19/patritumab-deruxtecan-falls-short-in-egfrm-nsclc/) - Patritumab deruxtecan did not improve overall survival compared to chemotherapy in EGFR-mutated NSCLC, despite showing PFS and ORR benefits previously.
- [The Overlooked Issues Faced by Women with Lung Cancer](https://egfrcancer.org/2025/11/19/the-overlooked-issues-faced-by-women-with-lung-cancer/) - Despite being traditionally associated with older men and tobacco use, lung cancer rates are rising among women—particularly younger women.
- [Member Spotlight: Valerie Brown](https://egfrcancer.org/2025/11/19/member-spotlight-valerie-brown/) - Valerie Brown’s life with lung cancer began in 2012, with a cough.
- [EGFR SPOTLIGHT:  Dr. Bryant Lin](https://egfrcancer.org/2025/11/19/egfr-spotlight-dr-bryant-lin/) - Dr. Bryant Lin's goal is to live long enough to benefit from the next treatment breakthrough—and the next.
- [Redefining Cancer Survivorship](https://egfrcancer.org/2025/11/19/redefining-cancer-survivorship/) - WHEN JILL FELDMAN’S FATHER was diagnosed with lung cancer in the early 1980s, he lived just three months after his diagnosis. Fifteen years later, her mother developed the same cancer and lived six months. Feldman herself was diagnosed with stage I lung cancer in 2009, and she has lived 16 years beyond her diagnosis.
- [Project PRIORITY](https://egfrcancer.org/2025/11/19/project-priority/) - Our new interactive tool that brings Project PRIORITY survey data to life - highlighting the lived experiences of people with EGFR-positive NSCLC. It captures key insights around treatment patterns, diagnostic journeys, and side effects.
- [Design and discovery of BH-30643: A novel, reversible, mutant-selective macrocyclic EGFR inhibitor invulnerable to common resistance mutations](https://egfrcancer.org/2025/11/19/design-and-discovery-of-bh-30643-a-novel-reversible-mutant-selective-macrocyclic-egfr-inhibitor-invulnerable-to-common-resistance-mutations/) - To increase the breadth and durability of EGFR TKIs in EGFR mutant NSCLC, we have designed a novel reversible macrocyclic scaffold that fully leverages the characteristics of EGFR active conformation and introduces novel and precise interactions with mutant EGFRs via a three-dimensional macrocyclic structure.
- [ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate](https://egfrcancer.org/2025/11/19/alx-oncology-receives-ind-clearance-from-u-s-fda-for-alx2004-a-novel-egfr-targeted-antibody-drug-conjugate/) - ALX Oncology has received FDA clearance for its Investigational New Drug (IND) application for ALX2004, a potential first-in-class ADC for treating EGFR-expressing solid tumors.
- [COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities](https://egfrcancer.org/2025/11/19/cocoon-regimen-demonstrates-improvement-in-dermatologic-toxicities/) - The ongoing COCOON study of a prophylactic dermatologic regimen in reducing the incidence of skin- and nail-adverse reactions in patients treated with amivantamab plus lazertinib demonstrated “early success” in meeting its phase II primary endpoint, according to a March 27 presentation during the European Lung Cancer Congress (ELCC).
- [Novel TKI Highly Active in HER2-Mutant Lung Cancer](https://egfrcancer.org/2025/11/19/novel-tki-highly-active-in-her2-mutant-lung-cancer/) - The investigational oral TKI zongertinib showed promise in patients with previously treated HER2-mutant NSCLC in a multicohort phase Ia/Ib study.
- [Amivantamab/Lazertinib Shows OS and PFS Benefits in EGFR-Mutated NSCLC](https://egfrcancer.org/2025/11/19/amivantamab-lazertinib-shows-os-and-pfs-benefits-in-egfr-mutated-nsclc/) - Xiuning Le, MD, PhD, discusses updated intracranial efficacy, overall survival, and safety of amivantamab + lazertinib in patients with EGFR+ NSCLC.
- [AACR 2025 Highlights](https://egfrcancer.org/2025/11/19/aacr-2025-highlights/) - In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Christine Lovly discuss significant lung cancer findings presented at the AACR 2025 Annual Meeting.
- [EGFR Resisters Co-Founder Ivy Elkins' Legacy Lives on at AACR 2025](https://egfrcancer.org/2025/11/19/egfr-resisters-co-founder-ivy-elkins-legacy-lives-on-at-aacr-2025/) - Ivy's voice helped shape research, and now her cells are helping to drive progress - - a full circle moment.
- [Diagnosed with Lung Cancer? 10 Must Read Tips to be an Empowered Patient](https://egfrcancer.org/2025/11/19/diagnosed-with-lung-cancer-10-must-read-tips-to-be-an-empowered-patient/) - Information and support are key to being an empowered patient and optimizing treatment outcomes.
- [How EGFR+ NSCLC Can Transform Into SCLC](https://egfrcancer.org/2025/11/19/how-egfr-nsclc-can-transform-into-sclc/) - Learn about the latest research on how NSCLC can transform into SCLC and how that can impact treatment options from Jacob Berchuck, MD.
- [Tepotinib plus an EGFR tyrosine kinase inhibitor in patients with EGFR-mutant MET-altered NSCLC: A case series](https://egfrcancer.org/2025/11/19/tepotinib-plus-an-egfr-tyrosine-kinase-inhibitor-in-patients-with-egfr-mutant-met-altered-nsclc-a-case-series/) - Acquired EGFR-TKI resistance is commonly mediated by MET alterations, with MET amplification (METamp) the most frequent cause of bypass pathway activation.
- [Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC](https://egfrcancer.org/2025/11/19/nuvectis-pharma-announces-a-new-publication-of-a-research-study-demonstrating-that-the-combination-of-nxp900-and-egfr-inhibitors-improves-the-efficacy-of-the-egfr-inhibitors-in-preclinical-models-of-e/) - The combination of NXP900 and osimertinib was superior to single agent osimertinib in vivo in a model of EGFR+ NSCLC and led to decreased cell proliferation and increased apoptosis in vitro.
- [CAR-NK: bringing cellular immunotherapy to the masses](https://egfrcancer.org/2025/11/19/car-nk-bringing-cellular-immunotherapy-to-the-masses/) - CAR-NK therapies offer the promise of off-the-shelf cancer treatments, addressing the drawbacks of patient-specific CAR-T cells.
- [Radiation and Leptomeningeal Disease](https://egfrcancer.org/2025/11/19/radiation-and-leptomeningeal-disease/) - Learn the difference between proton and photon therapy, how treatment plans are developed, and the latest in clinical trials.
- [FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer](https://egfrcancer.org/2025/11/19/fda-grants-orphan-drug-designation-to-rhenium-186re-obisbemeda-for-leptomeningeal-metastases-in-lung-cancer/) - The FDA has granted orphan drug designation to the investigational radiotherapeutic rhenium (186Re) obisbemeda as a potential therapeutic option for LMD metastases in lung cancer patients.
- [Updates on MARIPOSA AND MARIPOSA2](https://egfrcancer.org/2025/11/19/updates-on-mariposa-and-mariposa2/) - Updates on MARIPOSA, MARAIPOSA2, and COCOON studies for EGFR+ lung cancer.
- [Adding Dato-DXd After Progression on Osimertinib Improves PFS in EGFR-Mutated NSCLC Trial](https://egfrcancer.org/2025/11/19/adding-dato-dxd-after-progression-on-osimertinib-improves-pfs-in-egfr-mutated-nsclc-trial/) - Early efficacy data from the phase 2 ORCHARD platform trial suggest that adding datopotamab deruxtecan to osimertinib may stave off disease progression longer than other combinations.
- [Finding My Happiness Despite Facing Lung Cancer](https://egfrcancer.org/2025/11/19/finding-my-happiness-despite-facing-lung-cancer/) - There is an endless list of things I would like to do while I am able and strong, things that give me happiness.
- [Lung Cancer in Women: Why We Need to #HearHer](https://egfrcancer.org/2025/05/20/lung-cancer-in-women-why-we-need-to-hearher-2/) - This message resonates deeply with women across the world who are courageously speaking out about their lung cancer journeys—their voices amplified by the recently launched #HearHer campaign.
- [How Can Patients and Researchers Design Clinical Trials Together?](https://egfrcancer.org/2025/05/20/how-can-patients-and-researchers-design-clinical-trials-together/) - In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials.
- [Member Spotlight: Jeff Stibelman](https://egfrcancer.org/2025/05/20/member-spotlight-jeff-stibelman/) - When he was diagnosed with lung cancer, Jeff Stibelman was told he’d live for 6 months, maybe a year. That was four years ago. Today Jeff is busy advocating for lung cancer patients and research.
- [FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC](https://egfrcancer.org/2025/05/18/fda-grants-priority-review-to-zongertinib-for-her2-mutant-advanced-nsclc/) - The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.
- [20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect](https://egfrcancer.org/2025/05/18/20-years-of-egfr-research-ramalingam-carbone-politi-janne-govindan-reflect/) - Podcast: Suresh S. Ramalingam, a lung cancer expert, executive director of Winship Cancer Institute of Emory University, and editor-in-chief of the journal Cancer, moderates a panel of people who played a role in the discovery of the EGFR mutation in lung cancer.
- [Potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC](https://egfrcancer.org/2025/05/18/potential-of-lazertinib-and-amivantamab-combination-therapy-as-a-treatment-strategy-for-uncommon-egfr-mutated-nsclc/) - This study presents preclinical evidence and mechanistic insights into the combination of lazertinib, a 3rd generation EGFR-TKI; and amivantamab, an EGFR-MET bispecific antibody, for treating NSCLC with uncommon EGFR mutations.
- [EGFR-Mutated Lung Cancer: Co-Mutations and Radiation for Brain Metastases](https://egfrcancer.org/2025/05/18/egfr-mutated-lung-cancer-co-mutations-and-radiation-for-brain-metastases/) - In this video, the panel discusses the role of radiation for brain metastases. They also discuss if, in addition to classical mutations for EGFR, looking at additional mutations can guide decision-making for treatment.
- [Air pollution drives lung cancer surge in non-smokers, study reveals](https://egfrcancer.org/2025/05/18/air-pollution-drives-lung-cancer-surge-in-non-smokers-study-reveals/) - Study: Air pollution is fueling a rise in the commonest form of lung cancer among non-smokers, hitting women and people in southeast Asia particularly hard.
- [Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance](https://egfrcancer.org/2025/05/18/virtual-tumor-board-treating-egfr-nsclc-after-tki-resistance/) - In this podcast of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC.
- [How Efficacious are Immunotherapies for EGFR-Mutated Lung Cancer? - 2024 Lung Cancer OncTalk](https://egfrcancer.org/2025/05/18/how-efficacious-are-immunotherapies-for-egfr-mutated-lung-cancer-2024-lung-cancer-onctalk/) - In this video, the panel discusses how efficacious immunotherapy is for EGFR-mutated lung cancer.
- [EGFR NSCLC Slide Decks from TTLC 2025](https://egfrcancer.org/2025/05/18/egfr-nsclc-slide-decks-from-ttlc-2025/) - Specific presentation decks from TTLC 2025 on EGFR+ NSCLC: CNS penetrants for Leptomeningeal disease, uncommon EGFR mutations, and EGFR resistance and second line therapy.
- [Family Discourse and Lung Cancer](https://egfrcancer.org/2025/05/18/family-discourse-and-lung-cancer/) - Many cancer questions don't initially include how the family will react, especially when there are unresolved family dynamics.
- [Member Spotlight: Theresa Flanagan](https://egfrcancer.org/2025/05/18/member-spotlight-theresa-flanagan/) - In 2014, Theresa Flanagan was about to start working with the elderly as part of her master’s degree thesis.
- [Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY](https://egfrcancer.org/2025/05/18/access-to-diagnostics-and-treatment-for-people-with-metastatic-egfr-positive-nsclc-lessons-from-project-priority/) - In this paper, we describe the clinical characteristics and treatment experiences of people living with EGFR-m lung cancer from Project PRIORITY, a patient-driven study.
- [2024 EGFR Resisters 6th Annual Research Summit Newsletter](https://egfrcancer.org/2025/05/18/2024-egfr-resisters-6th-annual-research-summit-newsletter/) - This special newsletter includes a summit recap and covers its agenda, including the Awardees and their research projects:
- [Pooled Data Show Sunvozertinib Potential in EGFR-Mutated NSCLC](https://egfrcancer.org/2025/05/16/pooled-data-show-sunvozertinib-potential-in-egfr-mutated-nsclc/) - Data from a pooled analysis evaluating sunvozertinib (DZD9008) show promising antitumor activity with a favorable safety profile for EGFR- TKI-resistant EXON 20 NSCLC.
- [REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point](https://egfrcancer.org/2025/05/16/rezilient1-study-of-zipalertinib-in-pretreated-egfr-mutant-nsclc-meets-orr-primary-end-point/) - Zipalertinib demonstrated a 40% ORR and 90% DCR in NSCLC patients with EGFR exon 20 insertion mutations, meeting the trial's primary endpoint.
- [TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting](https://egfrcancer.org/2025/05/16/tkis-look-to-solidify-a-role-alongside-t-dxd-in-the-second-line-her2-mutant-nsclc-setting/) - Treatments are rapidly evolving in 2ndline setting and beyond for patients with HER2-mutated non–small cell lung cancer (NSCLC), with several promising TKIs under development looking to join fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in this setting.
- [Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study](https://egfrcancer.org/2025/05/16/preventing-infusion-related-reactions-with-intravenous-amivantamab-results-from-skippirr-a-phase-2-study/) - Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced NSCLC as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reaction (IRR) rate.
- [Importance of Palliative Care with Dr. Laura Petrillo](https://egfrcancer.org/2025/05/16/importance-of-palliative-care-with-dr-laura-petrillo/) - The Young Lung Cancer Initiative hosted a webinar with Dr. Laura Petrillo, who is a palliative care physician at MGH in Boston, MA.
- [FDA Grants Priority Review to Dato-DXd in Advanced EGFR-Mutated NSCLC](https://egfrcancer.org/2025/05/16/fda-grants-priority-review-to-dato-dxd-in-advanced-egfr-mutated-nsclc/) - The FDA granted priority review to datopotamab deruxtecan in advanced EGFR-mutated NSCLC after prior therapies, with a decision expected by July 12, 2025.
- [Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib](https://egfrcancer.org/2025/05/16/results-from-a-phase-1b-study-of-telisotuzumab-vedotin-in-combination-with-osimertinib-in-patients-with-c-met-protein-overexpressing-egfr-mutated-locally-advanced-metastatic-non-small-cell-lu/) - In this article, we report the results of a phase I/Ib trial evaluating Teliso-V plus osimertinib in patients with NSCLC after progression on osimertinib.
- [Dr. Antonoff Shares Insights on Surgery for Stage IV Lung Cancer](https://egfrcancer.org/2025/05/16/dr-antonoff-shares-insights-on-surgery-for-stage-iv-lung-cancer/) - Mara B. Antonoff, MD, FACS, of the University of Texas MD Anderson Cancer Center discusses a session on operating in stage IV lung cancer.
- [Stephen Liu, MD, Discusses MARIPOSA Overall Survival Data](https://egfrcancer.org/2025/05/16/stephen-liu-md-discusses-mariposa-overall-survival-data/) - Video: Stephen Liu, MD, discusses the announcement that the phase 3 MARIPOSA trial met its final pre-specified secondary endpoint of overall survival (OS).
- [Getting Started in Lung Cancer Advocacy](https://egfrcancer.org/2025/05/16/getting-started-in-lung-cancer-advocacy/) - Here are some networks and recorded informational webinars on types of lung cancer advocacy, how to get training, and becoming more involved.
- [I Lost My Mom and Dad to Lung Cancer—Now I Have It](https://egfrcancer.org/2025/05/16/i-lost-my-mom-and-dad-to-lung-cancer-now-i-have-it/) - Diagnosed with lung cancer at just 39 years old, EGFR Resisters co-founder Jill Feldman recounts how her advocacy efforts before her diagnosis prepared her for the battle ahead.
- [Member Spotlight: Maggie McCloskey](https://egfrcancer.org/2025/05/16/member-spotlight-maggie-mccloskey/) - As Maggie McCloskey celebrated her 60th birthday, she told herself, “2021 is going to be the best year of my life!” But a slow cascade of puzzling health events began to test her certainty.
- [2024 EGFR Resisters Research Summit Wrap-up Video](https://egfrcancer.org/2025/05/16/2024-egfr-resisters-research-summit-wrap-up-video/) - Video: The EGFR Resisters just held our 6th annual EGFR Resistors Research Summit in December. We brought together young investigators from all across the country who are doing work related to EGFR+ lung cancer.
- [Loving Ourselves into Health©](https://egfrcancer.org/2019/03/17/loving-ourselves-into-health/) - Any real threat to our lives forces us to wake up, to look inside ourselves for meaning, for wisdom, for patience, for love.
- [Big News! Bigger Steps! Bold Action! EGFR Resisters Becoming a 501c3 Non-Profit](https://egfrcancer.org/2025/01/06/big-news-bigger-steps-bold-action-egfr-resisters-becoming-a-501c3-non-profit/) - As we welcome in we are thrilled to announce that EGFR Resisters is becoming an independent 501(c)(3) non-profit organization!
- [2021 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awards Update](https://egfrcancer.org/2025/01/06/2021-egfr-resisters-lungevity-foundation-egfr-positive-lung-cancer-research-awards-update/) - Dr. Christine Lovly is studying how EGFR+ NSCLC cells become resistant to osimertinib, and Dr. Helena Yu is examining histologic transformation as a resistance mechanism.
- [2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Award Year 1 Progress Update](https://egfrcancer.org/2025/01/06/2023-egfr-resisters-lungevity-foundation-egfr-positive-lung-cancer-research-award-year-1-progress-update/) - 2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awardees are studying how to target drug-tolerant persister cells (DTPCs).
- [How Biomarker Testing Could Continue to Evolve in NSCLC](https://egfrcancer.org/2024/12/21/how-biomarker-testing-could-continue-to-evolve-in-nsclc/) - Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss the next steps for biomarker testing in NSCLC.
- [Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC](https://egfrcancer.org/2024/12/21/dr-girard-on-de-novo-and-acquired-resistance-alterations-in-her2-altered-nsclc/) - Nicolas Girard, MD, discusses both de novo and acquired resistance alterations in HER2-altered non–small cell lung cancer.
- [FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC](https://egfrcancer.org/2024/12/21/fda-receives-new-bla-for-dato-dxd-in-pretreated-egfr-advanced-nsclc/) - AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.
- [Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–TkIs: A Multicenter, Randomized, Controlled, Phase III Trial](https://egfrcancer.org/2024/12/21/thoracic-radiotherapy-improves-the-survival-in-patients-with-egfr-mutated-oligo-organ-metastatic-non-small-cell-lung-cancer-treated-with-epidermal-growth-factor-receptor-tkis-a-multic-2/) - For patients with EGFR-mutated oligo-organ metastatic NSCLC treated with first-line EGFR-TKIs, concurrent TRT improves the PFS and OS, and TRAEs are acceptable and tolerable.
- [In the US, young and middle-aged women are being diagnosed with lung cancer at higher rates than men](https://egfrcancer.org/2024/12/21/in-the-us-young-and-middle-aged-women-are-being-diagnosed-with-lung-cancer-at-higher-rates-than-men/) - Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed.
- [Member Spotlight: Leigh Durant (Caregiver)](https://egfrcancer.org/2024/12/17/member-spotlight-leigh-durant-caregiver/) - Leigh Durant’s experience as the lung cancer caregiver for her mother, Alice Hughes, began in April 2024, when Alice told Leigh she just didn’t feel like herself.
- [Scientific Symposium Kicks off Lung Cancer Awareness Month](https://egfrcancer.org/2024/12/17/scientific-symposium-kicks-off-lung-cancer-awareness-month/) - LCRF’s 2024 Scientific Symposium was held November 4 as part of our Lung Cancer Awareness Month activities.
- [Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–TkIs: A Multicenter, Randomized, Controlled, Phase III Trial](https://egfrcancer.org/2024/12/17/thoracic-radiotherapy-improves-the-survival-in-patients-with-egfr-mutated-oligo-organ-metastatic-non-small-cell-lung-cancer-treated-with-epidermal-growth-factor-receptor-tkis-a-multic/) - For patients with EGFR-mutated oligo-organ metastatic NSCLC treated with first-line EGFR-TKIs, concurrent TRT improves the PFS and OS, and TRAEs are acceptable and tolerable.
- [New tool predicts risk of lung cancer’s spread to brain](https://egfrcancer.org/2024/12/17/new-tool-predicts-risk-of-lung-cancers-spread-to-brain/) - In a new study published in Nature Medicine UHN researchers have identified specific DNA changes that can predict a patient’s risk of cancer spreading to the brain, offering new approaches to managing patients and improving health outcomes.
- [Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development](https://egfrcancer.org/2024/12/17/advancements-in-fourth-generation-egfr-tkis-in-egfr-mutant-nsclc-bridging-biological-insights-and-therapeutic-development/) - Fourth-generation EGFR-TKIs are active against common and resistance EGFR mutations.
- [Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC](https://egfrcancer.org/2024/12/17/osimertinib-plus-savolitinib-generates-durable-responses-in-egfr-mutant-met-amplified-nsclc/) - Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.
- [Choosing Treatment After Osimertinib for Patients With EGFR-Mutated NSCLC With MET Amplification](https://egfrcancer.org/2024/12/16/choosing-treatment-after-osimertinib-for-patients-with-egfr-mutated-nsclc-with-met-amplification/) - Dual anti-EGFR/anti-MET inhibition may be an optimal approach upon osimertinib disease progression, with amivantamab-based strategies showing particular promise.
- [Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC](https://egfrcancer.org/2024/12/16/lung-cancer-esmo-2024-highlights-key-studies-discussed-laura-mariposa-mariposa-2-adriatic/) - Hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center todive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of.
- [First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC](https://egfrcancer.org/2024/12/16/first-patients-dosed-in-new-phase-3-trials-of-dato-dxd-in-nsclc/) - Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.
- [STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment](https://egfrcancer.org/2024/12/16/stx-241-trial-begins-for-egfr-tki-resistant-nsclc-treatment/) - A phase 1/2 trial (NCT06567015) evaluating STX-241 (PFL-241) for the treatment of EGFR inhibitor-resistant non–small cell lung cancer (NSCLC) has dosed its first patient.
- [Exciting New Treatments for EGFR+ NSCLC on the Horizon](https://egfrcancer.org/2024/12/16/exciting-new-treatments-for-egfr-nsclc-on-the-horizon/) - This recorded webinar discusses how immune cells can be engineered to target EGFR+ NSCLC.
- [Patient Education Webcast: Misconceptions of Clinical Trials](https://egfrcancer.org/2024/12/16/patient-education-webcast-misconceptions-of-clinical-trials/) - In this recorded webinar, oncologist and executive medical director, Dr. Julio Hajdenberg from Black Diamond Therapeutics joined Stage IV EGFR lung cancer patients Leah Phillips and Karly Renn to explore common misconceptions about clinical trials.
- [Member Spotlight: Stephanie D’Elia](https://egfrcancer.org/2024/12/15/member-spotlight-stephanie-delia/) - Stephanie D’Elia is a microbiologist with a passion for bacteria. She loves seeing how much bacteria will grow in test tubes or on petri dishes, and what those growths will look like. She also enjoys the colorful reactions that can occur in the test tubes because of the metabolism of bacteria and the contents of the tube. But Stephanie’s ability to work in the field changed in 2023, when she was diagnosed with Stage IV EGFR + lung cancer.
- [Novel TKI Exhibits Durable Responses in HER2-Mutated NSCLC](https://egfrcancer.org/2024/12/15/novel-tki-exhibits-durable-responses-in-her2-mutated-nsclc/) - BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.
- [Amivantamab Combo Reduces Symptom Progression in EGFR-Mutated NSCLC](https://egfrcancer.org/2024/12/15/amivantamab-combo-reduces-symptom-progression-in-egfr-mutated-nsclc/) - Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.
- [Firmonertinib Yields Responses in EGFR-Mutant NSCLC Subtype](https://egfrcancer.org/2024/12/15/firmonertinib-yields-responses-in-egfr-mutant-nsclc-subtype/) - Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.
- [WCLC 2024: Analyzing SKIPPirr Data Outcomes for Lung Cancer Advancements](https://egfrcancer.org/2024/12/15/wclc-2024-analyzing-skippirr-data-outcomes-for-lung-cancer-advancements/) - Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.
- [ESMO 2024: Latest in EGFR mutated NSCLC](https://egfrcancer.org/2024/12/15/esmo-2024-latest-in-egfr-mutated-nsclc/) - In this video update, The panel covers updates from the MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr studies, and also explores treatment options for EGFR mutated NSCLC with exon 20 insertions.
- [Oncogene-addicted NSCLC update from WCLC and ESMO 2024](https://egfrcancer.org/2024/12/15/oncogene-addicted-nsclc-update-from-wclc-and-esmo-2024/) - In this video update, Dr Herbert H. Loong shares his perspective on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) to emerge from two important congresses, WCLC and ESMO 2024.
- [FDA Approves Amivantamab Plus Chemo for EGFR+ Advanced NSCLC After an EGFR Inhibitor](https://egfrcancer.org/2024/12/15/fda-approves-amivantamab-plus-chemo-for-egfr-advanced-nsclc-after-an-egfr-inhibitor/) - The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.
- [FDA Approves Osimertinib in Stage III EGFR-Mutated NSCLC](https://egfrcancer.org/2024/12/15/fda-approves-osimertinib-in-stage-iii-egfr-mutated-nsclc/) - Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that did not progress during or following platinum-based chemoradiation.
- [Black Diamond Therapeutics' Lead Drug Candidate (BDTX-1535) Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug](https://egfrcancer.org/2024/12/15/black-diamond-therapeutics-lead-drug-candidate-bdtx-1535-shows-initial-anti-tumor-activity-in-certain-type-of-lung-cancer-resistant-to-astrazenecas-drug/) - The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR) NSCLC.
- [Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC](https://egfrcancer.org/2024/12/15/patritumab-deruxtecan-meets-pfs-end-point-in-pretreated-egfr-mutant-nsclc/) - The investigational HER​​3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) elicited a statistically significant improvement in progression-free survival (PFS) vs platinum-based chemotherapy in patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who were previously exposed to an EGFR TKI, meeting the primary end point of the phase 3 HERTHENA-Lung02 trial (
- [Managing Lung Cancer in Young Adults: Not a Sprint but a Marathon](https://egfrcancer.org/2024/12/14/managing-lung-cancer-in-young-adults-not-a-sprint-but-a-marathon/) - What happens when a disease that is tied to a more "vintage" population crops up in younger people?
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://egfrcancer.org/2024/12/14/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without-pembrolizumab-for-tyrosine-kinase-inhibitor‒resistant-egfr-mutant-metastatic-nonsquamous-non-small-cell/) - Results from the phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC.
- [Osimertinib Offers New Standard of Care in Stage III EGFR-Mutated NSCLC](https://egfrcancer.org/2024/12/14/osimertinib-offers-new-standard-of-care-in-stage-iii-egfr-mutated-nsclc/) - The phase 3 LAURA study showed that osimertinib (Tagrisso) significantly extends survival for patients with unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutations.
- [Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer](https://egfrcancer.org/2024/12/14/amivantamab-lazertinib-shows-potential-in-atypical-egfr-mutant-lung-cancer/) - Cohort C of the CHRYSALIS-2 study (NCT04077463) investigated the combination of amivantamab (Rybrevant) and lazertinib (Leclaza), which has proven efficacy in more common EGFR mutations, in patients with these atypical mutations.
- [Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis](https://egfrcancer.org/2024/12/14/efficacy-and-safety-of-immune-checkpoint-inhibitors-for-individuals-with-advanced-egfr-mutated-non-small-cell-lung-cancer-who-progressed-on-egfr-tyrosine-kinase-inhibitors-a-systematic-review-meta-a/) - The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in treating individuals with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who have progressed on EGFR tyrosine-kinase inhibitors (TKIs) remain controversial.
- [Weighing Chemo Risks: Post-op Adjuvant and Stage IV Settings](https://egfrcancer.org/2024/12/14/weighing-chemo-risks-post-op-adjuvant-and-stage-iv-settings/) - Mark Kris, from Memorial Sloan Kettering, speaks about the use of chemotherapy with a targeted therapy, particularly in patients with EGFR and ALK mutations.
- [PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up](https://egfrcancer.org/2024/12/14/prpc-controls-epithelial-to-mesenchymal-transition-in-egfr-mutated-nsclc-implications-for-tki-resistance-and-patient-follow-up/) - We hypothesized that the cellular prion protein PrPC could be involved in EMT and EGFR-TKI resistance in NSCLC.
- [Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases](https://egfrcancer.org/2024/12/14/emerging-novel-diagnostic-and-therapeutic-approaches-for-leptomeningeal-metastases/) - This recorded event will delve into cutting-edge advancements in the diagnosis and treatment of Leptomeningeal Metastases
- [FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer](https://egfrcancer.org/2024/12/14/fda-approves-lazertinib-with-amivantamab-vmjw-for-non-small-lung-cancer/) - The FDA approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic NSCLC with EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
- [Final analysis data and exploratory biomarker analysis of a randomized phase II study of osimertinib + bevacizumab vs osimertinib monotherapy for untreated patients with non-squamous NSCLC harboring EGFR mutations](https://egfrcancer.org/2024/12/14/final-analysis-data-and-exploratory-biomarker-analysis-of-a-randomized-phase-ii-study-of-osimertinib-bevacizumab-vs-osimertinib-monotherapy-for-untreated-patients-with-non-squamous-nsclc-harboring-e/) - This study showed final analysis survival data, biomarkers and resistance mechanisms of osimertinib plus bevacizumab or osimertinib monotherapy in previously untreated patients with advanced EGFR-positive non-squamous NSCLC.
- [FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC](https://egfrcancer.org/2024/12/14/fda-grants-zongertinib-breakthrough-therapy-designation-in-her2-mutant-nsclc/) - New data on zongertinib for HER2-positive non–small cell lung cancer will be presented at the IASLC 2024 World Conference on Lung Cancer, shedding light on its potential as a novel treatment option for this patient population.
- [FDA Grants Fast Track Designation to Deltacel and Radiation in NSCLC](https://egfrcancer.org/2024/12/14/fda-grants-fast-track-designation-to-deltacel-and-radiation-in-nsclc/) - Following promising data from the phase 1 Deltacel-01 trial, the FDA has given Deltacel plus low-dose radiation therapy a fast track designation in stage IV non–small cell lung cancer.
- [Podcast: MARIPOSA for EGFR+ Lung Cancer](https://egfrcancer.org/2024/10/06/podcast-mariposa-for-egfr-lung-cancer/) - MARIPOSA, a study that combined the dual EGFR-MET bispecific antibody amivantamab with the CNS-penetrant anti-EGFR TKI lazertinib, and uniquely compared it to osimertinib. Will this combination dethrone the king and rule the roost in EGFRmut NSCLC?
- [Member Spotlight: Karen LaBonté](https://egfrcancer.org/2024/10/06/member-spotlight-karen-labonte/) - By February 8, 2021, I had had enough. After 6 weeks of a cough that just wouldn’t quit, several doctor appointments, all the typical asthma treatments that had no effect, I took myself to immediate care and said I needed a chest X-ray.
- [PALOMA-3: Subcutaneous Amivantamab in Refractory EGFR+ Advanced NSCLC](https://egfrcancer.org/2024/10/06/paloma-3-subcutaneous-amivantamab-in-refractory-egfr-advanced-nsclc/) - Watch expert perspectives (and pros and cons) on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer.
- [Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer](https://egfrcancer.org/2024/10/06/long-qt-syndrome-after-using-egfr-tkis-in-older-patients-with-advanced-non-small-cell-lung-cancer/) - Long QT syndrome (LQTS) has been reported in older patients with advanced NSCLCfollowing the use of osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
- [Trastuzumab deruxtecan in HER2 NSCLC: plain language summary of the DESTINY-Lung01 study](https://egfrcancer.org/2024/10/06/trastuzumab-deruxtecan-in-her2-nsclc-plain-language-summary-of-the-destiny-lung01-study/) - Results from the DESTINY-Lung01 study showed that 55% of participants responded to treatment with T-DXd.
- [Uniqueness of lung cancer in Southeast Asia](https://egfrcancer.org/2024/10/06/uniqueness-of-lung-cancer-in-southeast-asia/) - To better understand the profile of lung cancer in Southeast Asia, with a focus on India, we have comprehensively reviewed the available data, and discuss the challenges and the way forward.
- [Podcast: Immunotherapy in Driver-Positive NSCLC](https://egfrcancer.org/2024/10/06/podcast-immunotherapy-in-driver-positive-nsclc/) - In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular driven non-small cell lung cancer.
- [Treatment sequences in EGFR mutant advanced NSCLC](https://egfrcancer.org/2024/10/05/treatment-sequences-in-egfr-mutant-advanced-nsclc/) - Several strategies are currently developed: prevent the emergence of resistance mechanisms by therapeutic combinations introduced from the first line, act on the residual disease at the time of maximum response to 1st line treatment, develop therapeutic strategies at the time of acquired resistance to TKIs, either dependent on the resistance mechanisms, or agnostic of the resistance pathways.
- [Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC](https://egfrcancer.org/2024/10/05/lp-300-plus-chemo-yields-early-efficacy-results-in-never-smokers-with-nsclc-2/) - Health Canada has approved osimertinib (Tagrisso) in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations.
- [2024 ASCO Annual Meeting Recap](https://egfrcancer.org/2024/10/05/2024-asco-annual-meeting-recap/) - In this recorded Webcast, Drs. Benjamin Levy, Antoinette (Toni) Wozniak, and Isabel Preeshagul gave an insightful recap NSCLC highlightsof the ASCO Annual Meeting.
- [LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC](https://egfrcancer.org/2024/10/05/lp-300-plus-chemo-yields-early-efficacy-results-in-never-smokers-with-nsclc/) - LP-300 plus pemetrexed/carboplatin exhibited disease control in never-smokers with advanced NSCLC following progression on prior TKI treatment.
- [Advocacy 101: Introduction to Advocacy with Jill Feldman](https://egfrcancer.org/2024/10/05/advocacy-101-introduction-to-advocacy-with-jill-feldman/) - Begin your lung cancer advocacy journey here by viewing this webcast.
- [FDA Issues CRL for Patritumab Deruxtecan in Pretreated EGFR+ NSCLC](https://egfrcancer.org/2024/10/05/fda-issues-crl-for-patritumab-deruxtecan-in-pretreated-egfr-nsclc/) - The FDA has issued a complete response letter to the biologics license application seeking the approval of patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR mutations who previously received 2 or more systemic therapies.
- [Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)](https://egfrcancer.org/2024/10/05/activity-of-osimertinib-in-non-small-cell-lung-cancer-with-uncommon-epidermal-growth-factor-receptor-mutations-retrospective-observational-multicenter-study-articuno/) - The ARTICUNO study confirms the activity of osimertinib in patients with uEGFR, especially in those with compound uncommon–common mutations, or major uEGFR, even in the presence of BMs.
- [FDA Considers Subcutaneous Amivantamab in EGFR-Mutated NSCLC](https://egfrcancer.org/2024/10/05/fda-considers-subcutaneous-amivantamab-in-egfr-mutated-nsclc/) - A BLA for a fixed combination of amivantamab with recombinant human hyaluronidase for SC amivantamab has been submitted to the FDA for all currently approved or submitted indications of IV amivantamab in certain patients with NSCLC.
- [Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC](https://egfrcancer.org/2024/10/05/real-world-outcomes-of-pemetrexed-platinum-chemotherapy-plus-osimertinib-after-progression-on-first-line-osimertinib-in-advanced-egfr-mutated-nsclc/) - First-line pemetrexed-platinum chemotherapy + osimertinib(Pem-Plat-Osi) improves progression-free survival as compared to osimertinib alone in advanced epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC).
- [Second Analysis of FLAURA2 Extends Benefit of Osimertinib Combo in NSCLC](https://egfrcancer.org/2024/10/04/second-analysis-of-flaura2-extends-benefit-of-osimertinib-combo-in-nsclc/) - Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated NSCLCr in the phase 3 FLAURA2 study.
- [FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC](https://egfrcancer.org/2024/10/04/fda-grants-priority-review-to-osimertinib-for-egfr-stage-iii-nsclc/) - Osimertinib significantly improved PFS in unresectable, stage III NSCLC with EGFR mutations post-chemoradiotherapy.
- [Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer](https://egfrcancer.org/2024/10/04/experts-discuss-groundbreaking-advances-in-egfr-mutant-lung-cancer/) - A roundtable discussion with three lung cancer experts delving into the LAURA trial's impact and other promising EGFR targeted therapies
- [The Shifting Paradigm in Metastatic Ocogene-Driven NSCLC: Is Surgery an Option?](https://egfrcancer.org/2024/10/04/the-shifting-paradigm-in-metastatic-ocogene-driven-nsclc-is-surgery-an-option/) - Recorded webinar with MD Anderson thoracic surgeon, Mara Antonoff and thoracic oncologist, Carl Gay, to discuss surgery as an option in advanced mutation-driven lung cancer.
- [Inherited Lung Cancer Risk Recorded Webinar](https://egfrcancer.org/2024/10/04/inherited-lung-cancer-risk-recorded-webinar/) - People who have lung cancer or who have had relatives diagnosed with lung cancer hear from the study investigators, Dr. Pasi Janne and Dr. Jaclyn LoPiccolo. They share an overview of the study and information on who qualifies.
- [A Tribute to Ivy Elkins by Jill Feldman](https://egfrcancer.org/2024/10/04/a-tribute-to-ivy-elkins-by-jill-feldman/) - Lung Cancer has taken yet another bright light from our world: a beautiful soul. But it can never take away Ivy's impact on countless lives, a testament to her strength and resilience that continues to inspire us all.
- [LAURA clinical trial sets new standard of care for advanced lung cancer](https://egfrcancer.org/2024/10/04/laura-clinical-trial-sets-new-standard-of-care-for-advanced-lung-cancer/) - Osimertinib (Tagrisso,) significantly extends the time patients live without their cancer worsening, offering the first effective therapy and new hope for those with stage III EGFR+ NSCLC
- [Amivantamab + Lazertinib in Patients with EGFR NSCLC and CNS Disease](https://egfrcancer.org/2024/10/04/amivantamab-lazertinib-in-patients-with-egfr-nsclc-and-cns-disease/) - Dr. Helena Yu's presentation shows this combo is a promising treatment for patients with brain mets and/or leptomeningeal disease (LM) after first-line treatment for clinical meaningful rate of time on treatment and radiographic response.
- [Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial (HARMONi)](https://egfrcancer.org/2024/10/04/ivonescimab-plus-chemotherapy-in-non-small-cell-lung-cancer-with-egfr-variant-a-randomized-clinical-trial-harmoni/) - Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with NSCLC who previously underwent EGFR-TKI treatment and may offer a new treatment option for patients with TKI resistance.
- [Treatment at the Time of Resistance to EGFR TKIs](https://egfrcancer.org/2024/10/04/treatment-at-the-time-of-resistance-to-egfr-tkis/) - This is an excellent presentation at ASCO 2024 by Dr. Jordi Remon Masip on treatment at time of resistance to EGFR TKIs. Those of you wanting to know what the latest is in options after progression on Tagrisso should look at the slide deck of his presentation.
- [Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)](https://egfrcancer.org/2024/10/04/phase-ii-efficacy-and-safety-of-80-mg-osimertinib-in-patients-with-leptomeningeal-metastases-associated-with-epidermal-growth-factor-receptor-mutation-positive-non-small-cell-lung-canc/) - This investigation evaluates the efficacy, safety, and pharmacokinetics of 80 mg once daily osimertinib in patients with LMs resistant to prior first- or second-generation EGFR TKIs.
- [Telehealth Equally Effective as In-Person Palliative Care in Maintaining Quality of Life in Patients With Advanced Lung Cancer](https://egfrcancer.org/2024/10/04/telehealth-equally-effective-as-in-person-palliative-care-in-maintaining-quality-of-life-in-patients-with-advanced-lung-cancer/) - A randomized comparative effectiveness trial confirmed that early palliative care delivered through video is just as effective as in-person visits on maintaining quality of life in patients with advanced lung cancer.
- [Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2](https://egfrcancer.org/2024/10/04/amivantamab-plus-lazertinib-in-atypical-egfr-mutated-advanced-non-small-cell-lung-cancer-nsclc-results-from-chrysalis-2/) - In the CHRYSALIS-2 study, amivantamab plus lazertinib demonstrated significant antitumor activity, including a 51% ORR and durable responses, in patients with atypical EGFR NSCLC, regardless of prior treatment with afatinib.
- [Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study](https://egfrcancer.org/2024/10/04/amivantamab-plus-lazertinib-vs-osimertinib-in-first-line-egfr-mutant-advanced-non-small-cell-lung-cancer-nsclc-with-biomarkers-of-high-risk-disease-a-secondary-analysis-from-the-phase-3-mariposa-st/) - Amivantamab combined with lazertinib significantly improved PFSl compared to osimertinib in treatment-naïve patients with EGFR advanced NSCLC, including those with high-risk features, establishing it as a promising new standard of care.
- [Subcutaneous Amivantamab Plus Lazertinib Maintains Efficacy With Improved Safety and Convenience VS Intravenous Administration in NSCLC (PALOMA-3)](https://egfrcancer.org/2024/07/11/subcutaneous-amivantamab-plus-lazertinib-maintains-efficacy-with-improved-safety-and-convenience-vs-intravenous-administration-in-nsclc-paloma-3/) - In patients with EGFR-m advanced NSCLC, subcutaneous amivantamab plus lazertinib is noninferior to IV amivantamab, as assessed by pharmacokinetics and ORR, according to results from the phase 3 PALOMA-3 trial.
- [Bispecific Combination Therapy Leads Paradigm Shift in Advanced NSCLC](https://egfrcancer.org/2024/07/11/bispecific-combination-therapy-leads-paradigm-shift-in-advanced-nsclc/) - Amivantamab + chemotherapy is becoming a popular option after osimertinib in EGFRm NSCLC.
- [Lung Cancer Patient Expert Q&A: Dr. Christina Baik](https://egfrcancer.org/2024/07/11/lung-cancer-patient-expert-qa-dr-christina-baik/) - In this recorded START HERE lung cancer webinar, Dr. Christina Baik, Associate Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Center, provides valuable insights into priorities for newly diagnosed patients.
- [Clinician Spotlight: Dr. Zosia Piotrowska](https://egfrcancer.org/2024/07/11/clinician-spotlight-dr-zosia-piotrowska/) - This month, we are honored to feature Dr. Zosia Piotrowska, MD, MHS. Dr Piotrowska is a medical oncologist at Massachusetts General Hospital and an Instructor of Medicine at Harvard Medical School.
- [Learning from the Legends: Lung Cancer Advocacy](https://egfrcancer.org/2024/07/11/learning-from-the-legends-lung-cancer-advocacy/) - This video is the project of an IASLC Patient Educational Award winner Yvonne Diaz, aimed at encouraging more advocacy efforts in lung cancer.
- [Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC](https://egfrcancer.org/2024/07/11/savolitinib-osimertinib-yields-responses-in-egfr-mutant-met-amplified-osimertinib-resistant-nsclc/) - Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.
- [Toxicities in Antibody Drug Conjugate Treatment](https://egfrcancer.org/2024/07/10/toxicities-in-antibody-drug-conjugate-treatment/) - In this video, Dr. Lyudmila Bazhenova discusses toxicities associated with antibody-drug conjugate treatment in NSCLC.
- [Safety and Feasibility of Stereotactic Radiosurgery for Patients with 15 or more Brain Metastases](https://egfrcancer.org/2024/07/10/safety-and-feasibility-of-stereotactic-radiosurgery-for-patients-with-15-or-more-brain-metastases/) - We present here one of the largest studies evaluating SRS for patients with ≥15 BMs. SRS was safe, had favorable cognitive outcomes, and comparable survival outcomes to contemporary studies evaluating WBRT in this population.
- [Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC](https://egfrcancer.org/2024/07/09/unlocking-the-potential-of-her3-targeted-therapy-breakthroughs-in-egfr-mutant-nsclc/) - In this video, Drs. Pasi Janne and Jyoti Patel unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC.
- [If You Have “One Shot on Goal” in EGFR-Mutated NSCLC, Which Approach Is Best?](https://egfrcancer.org/2024/07/09/if-you-have-one-shot-on-goal-in-egfr-mutated-nsclc-which-approach-is-best/) - In this video, lung cancer experts discuss how results from the FLAURA2 trial and the MARIPOSA trial have expanded options but also introduced important questions in EGFR+ NSCLC.
- [LP-300 in Never Smoker Population with Non-Small Cell Lung Cancer with Dr. Treat from FCCC](https://egfrcancer.org/2024/07/09/lp-300-in-never-smoker-population-with-non-small-cell-lung-cancer-with-dr-treat-from-fccc/) - In this video, Dr. Joseph Treat from Fox Chase Cancer Center discusses the LP-300 clinical trial regarding EGFR+ NSCLC in the never smoker population.
- [Schneider Urges Closer Review of Mechanisms of Resistance in Relapsed NSCLC](https://egfrcancer.org/2024/07/09/schneider-urges-closer-review-of-mechanisms-of-resistance-in-relapsed-nsclc/) - Though osimertinib is the preferred frontline approach to treatment for those with NSCLC with classic EGFR mutations, acquired resistance mechanisms invariably develop.
- [Clinician Spotlight: Dr. Alexandre Reuben](https://egfrcancer.org/2024/07/08/clinician-spotlight-dr-alexandre-reuben/) - This month, we are honored to feature Dr Alexandre Reuben, PhD, assistant professor in the Department of Thoracic/Head & Neck Medical Oncology at MD Anderson Cancer Center.
- [Listening to the Patient's Voice](https://egfrcancer.org/2024/07/08/listening-to-the-patients-voice/) - What does it mean to have a voice? In this podcast, Lauren Coye describes her experience of having been diagnosed with lung cancer at age 24 after years of symptoms. Her resilience and determination are an inspiration.
- [All About Oligoradiation and CURB](https://egfrcancer.org/2024/07/08/all-about-oligoradiation-and-curb/) - In this podcast, experts discuss radiation 101, describe what "oligo-" means in the context of oligoradiation, oligometastises & oligoprogression, the possibility of combining oligoradiation with other cancer treatments, and the CURB research study they're working on to test whether they could use stereotactic radiotherapy to stop oligoprogression.
- [Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions](https://egfrcancer.org/2024/07/08/amivantamab-lazertinib-still-effective-in-egfrm-nsclc-despite-dose-interruptions/) - According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
- [From osimertinib to preemptive combinations](https://egfrcancer.org/2024/07/08/from-osimertinib-to-preemptive-combinations/) - Here, I suggest that while first-line osimertinib extends median progression-free survival (mPFS) in EGFR-mutant lung cancer compared to 1st generation TKIs, it reduces individual PFS in 15–20% of patients compared to 1st generation TKIs.
- [Characteristics of Long-Term Survivors with EGFR Mutant Metastatic NSCLC](https://egfrcancer.org/2024/07/08/characteristics-of-long-term-survivors-with-egfr-mutant-metastatic-nsclc/) - This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors.
- [Lung cancer in patients who have never smoked — an emerging disease](https://egfrcancer.org/2024/07/08/lung-cancer-in-patients-who-have-never-smoked-an-emerging-disease/) - Lung cancer in individuals who have never smoked is estimated to be the fifth most common cause of cancer-related deaths worldwide in 2023, preferentially occurring in women and Asian populations.
- [Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC](https://egfrcancer.org/2024/07/08/experts-debate-addition-of-frontline-chemotherapy-for-egfr-nsclc/) - In light of data from FLAURA2 and MARIPOSA trials, Drs Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting.
- [IASLC’s 2024 Targeted Therapies of Lung Cancer Meeting Recap](https://egfrcancer.org/2024/07/08/iaslcs-2024-targeted-therapies-of-lung-cancer-meeting-recap/) - Stephen V. Liu, MD, Director of Thoracic Oncology and Head of Developmental Therapeutics, Georgetown University, gave an overview of the topics discussed during the 2024 IASLC Targeted Therapies Meeting. Isabel Preeshagul, DO, MBS, moderated the discussion.
- [Research Update: Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer](https://egfrcancer.org/2024/07/08/research-update-using-t-cells-to-tackle-drug-resistance-in-egfr-lung-cancer/) - Our goal is to use T cell engineering to stop DTPCs from growing and ultimately prevent the development of drug resistance in patients who are living with EGFR-positive lung cancer.
- [My Rock](https://egfrcancer.org/2024/07/08/my-rock/) - Juanita Segura, a lung cancer advocate, explains that no one understands us better than our lung cancer community.
- [Advocacy 101: Intro to Advocacy](https://egfrcancer.org/2024/07/08/advocacy-101-intro-to-advocacy/) - The American Society of Clinical Oncology (ASCO) has announced Jill Feldman, as the recipient of the 2024 ASCO Patient Advocate Award.
- [Jill Feldman Awarded the 2024 ASCO Patient Advocate Award](https://egfrcancer.org/2024/07/08/jill-feldman-awarded-the-2024-asco-patient-advocate-award/) - The American Society of Clinical Oncology (ASCO) has announced Jill Feldman, as the recipient of the 2024 ASCO Patient Advocate Award.
- [How One Type of Lung Cancer Can Transform into Another (NSCLC to SCLC)](https://egfrcancer.org/2024/07/08/how-one-type-of-lung-cancer-can-transform-into-another-nsclc-to-sclc/) - Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment.
- [Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor–Mutated Lung Cancer: Personalization, Parsimony, and Partnership](https://egfrcancer.org/2024/07/08/management-of-treatment-resistance-in-patients-with-advanced-epidermal-growth-factor-receptor-mutated-lung-cancer-personalization-parsimony-and-partnership/) - Despite EGFR TKIs' therapeutic successes, acquired treatment resistance and CNS progression are inevitable realities and a challenging transition in the cancer care continuum.
- [Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201](https://egfrcancer.org/2024/07/08/lazertinib-as-a-frontline-treatment-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-long-term-follow-up-results-from-laser201/) - This analysis demonstrated long-term clinical benefit with lazertinib 240 mg in patients with EGFR-mutated NSCLC who had not previously received EGFR TKIs.
- [Efficacy and safety of intrathecal pemetrexed (IP) for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial](https://egfrcancer.org/2024/07/08/efficacy-and-safety-of-intrathecal-pemetrexed-ip-for-tki-failed-leptomeningeal-metastases-from-egfr-nsclc-an-expanded-single-arm-phase-ii-clinical-trial/) - This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed for treating patients with leptomeningeal metastases from NSCLC who progressed from EGFR-TKI treatment in an expanded, prospective, single-arm, phase II clinical study
- [Primary and acquired resistance to first-line Osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies](https://egfrcancer.org/2024/07/08/primary-and-acquired-resistance-to-first-line-osimertinib-to-improve-the-outcome-of-egfr-mutated-advanced-non-small-cell-lung-cancer-patients-the-challenge-is-open-for-new-therapeutic-strategies/) - The study of primary and acquired resistance to front-line osimertinib is one of the main burning issues to further improve patients’ outcome.
- [Bring Hope Home](https://egfrcancer.org/2018/06/18/bring-hope-home/) - Lung Cancer Research & Educational Series
- [Osimertinib Combo Significantly Reduces CNS Progression in EGFRm NSCLC](https://egfrcancer.org/2024/07/07/osimertinib-combo-significantly-reduces-cns-progression-in-egfrm-nsclc/) - The FLAURA2 study found that osimertinib with platinum-pemetrexed was more effective than osimertinib alone in preventing central nervous system progression or death in advanced EGFR NSCLC patients.
- [Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC](https://egfrcancer.org/2024/07/07/partners-in-crime-co-occurring-genetic-alterations-in-egfr-mutant-nsclc/) - Co-occurring genetic alterations in solid tumors are a critical and influential prognostic factor that holds substantial importance in understanding the disease progression and guiding treatment strategies.
- [As cancer treatment advances, patients and doctors push back against drugs' harsh side effects](https://egfrcancer.org/2024/07/07/as-cancer-treatment-advances-patients-and-doctors-push-back-against-drugs-harsh-side-effects/) - Cancer patients and doctors have ignited a movement to radically change how new cancer drugs are tested to make them more tolerable.
- [FDA Approves Frontline Amivantamab Plus Chemo for EGFR Exon 20 Insertion+ NSCLC](https://egfrcancer.org/2024/07/07/fda-approves-frontline-amivantamab-plus-chemo-for-egfr-exon-20-insertion-nsclc/) - The FDA has approved amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or metastatic EGFR exon 20 NSCLC as detected by an FDA-approved test.
- [Empowering Lessons and Lung Cancer](https://egfrcancer.org/2024/07/07/empowering-lessons-and-lung-cancer/) - You aren’t the same person and it’s ok. This journey of cancer changes you. I like to think that it changes people for the better. We get to be in a place that allows us to embrace the good along the journey.
- [Research Project Update: EGFR Resisters + LCRF](https://egfrcancer.org/2024/07/07/research-project-update-egfr-resisters-lcrf/) - This recorded webinar is an update on EGFR+ NSCLC research supported by the EGFR Resisters and LCRF. Hear from 2022 grant recipients Dr. Swarnali Acharyya, Dr. Luke Hoeppner, and Dr. Jonathan Ostrem.
- [Germline EGFR Mutations and Familial Lung Cancer](https://egfrcancer.org/2024/07/07/germline-egfr-mutations-and-familial-lung-cancer/) - Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss this paper on germline EGFR mutations recently published in the JCO.
- [Oligometastatic NSCLC: Parts 1 and 2](https://egfrcancer.org/2024/07/07/oligometastatic-nsclc-parts-1-and-2/) - In these two podcasts, Dr. Narjust Florez discusses oligometastatic NSCLC and alternative treatments with lung cancer experts.
- [Osimertinib Resistance and EGFR Mutations in NSCLC Treatment](https://egfrcancer.org/2024/07/07/osimertinib-resistance-and-egfr-mutations-in-nsclc-treatment/) - This article discusses the analysis of circulating tumor DNA (ctDNA) in the context of osimertinib treatment for NSCLC, specifically focusing on resistance mechanisms.
- [FDA Accepts PMA Application Seeking Approval of TTFields Therapy in NSCLC for Filing](https://egfrcancer.org/2024/07/07/fda-accepts-pma-application-seeking-approval-of-ttfields-therapy-in-nsclc-for-filing/) - A premarket approval (PMA) application regarding the addition of tumor-treating fields (TTFields) to standard-of-care (SOC) therapies in patients with NSCLC after disease progression on or following platinum-based treatment has been accepted for filing by the FDA.
- [Novel Combinations Challenge Osimertinib Alone in EGFRm Lung Cancer](https://egfrcancer.org/2024/07/07/novel-combinations-challenge-osimertinib-alone-in-egfrm-lung-cancer/) - In the interview, Jonathan Riess, medical director of thoracic oncology, University of California, Davis Comprehensive Cancer Center, discussed the ever-changing EGFR+ lung cancer treatment landscape
- [Patritumab Deruxtecan Yields Meaningful, Enduring Activity in EGFR+ NSCLC](https://egfrcancer.org/2024/07/07/patritumab-deruxtecan-yields-meaningful-enduring-activity-in-egfr-nsclc/) - Treatment with patritumab deruxtecan (HER3-DXd) in patients with locally advanced / metastatic, EGFR+ NSCLC resulted in clinically meaningful efficacy and long-lasting responses following EGFR TKI therapy and platinum-based chemotherapy
- [Clinician Spotlight: Dr. Benjamin Herzberg](https://egfrcancer.org/2024/03/20/clinician-spotlight-dr-benjamin-herzberg/) - I am in awe of lung cancer patients and advocates, and I think they have made the world a better place when they have had limited time, resources, and a bad disease to fight. Keep it up.
- [New EGFR Resisters Lucky Shirts Now Available for Purchase!](https://egfrcancer.org/2024/03/20/new-egfr-resisters-lucky-shirts-now-available-for-purchase/) - Our new lucky shirts are meant to provide you with added confidence and hope when facing the challenges during your lung cancer journey. A percentage of purchase is donated to our research fund.
- [Only $100K to Go to Complete our Funding for Two Research Projects and We Now Get a Dollar for Dollar Match for our Donations!](https://egfrcancer.org/2024/03/20/only-100k-to-go-to-complete-our-funding-for-two-research-projects-and-we-now-get-a-dollar-for-dollar-match-for-our-donations/) - We are very pleased to announce a challenge grant: a $1 for $1 match of up to $50,000 from the Sally Rudney Memorial Fund.
- [Brief Report: Comprehensive Clinicogenetic Profiling of Small Cell Transformation from EGFR-mutant NSCLC Informs Potential Therapeutic Targets](https://egfrcancer.org/2024/03/20/brief-report-comprehensive-clinicogenetic-profiling-of-small-cell-transformation-from-egfr-mutant-nsclc-informs-potential-therapeutic-targets/) - In this study, we conducted a single-center retrospective analysis of clinical and genomic characteristics of patients with EGFR-mutant NSCLC transformed to SCLC.
- [Patritumab Deruxtecan BLA Receives Priority Review in NSCLC](https://egfrcancer.org/2024/03/20/patritumab-deruxtecan-bla-receives-priority-review-in-nsclc/) - The FDA has accepted and granted priority review to the biologics license application (BLA) seeking the approval of the HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR+NSCLC who previously received at least 2 systemic therapies.
- [sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC](https://egfrcancer.org/2024/03/20/sbla-and-nda-submitted-to-fda-for-amivantamab-and-lazertinib-in-egfr-mutant-nsclc/) - Amivantamab and Lazertinib may soon receive approval as a first-line treatment for EGFR+ lung cancer.
- [Ablative Radiotherapy Controls Resistant Non-Small Cell Lung Cancer in Clinical Trial](https://egfrcancer.org/2024/03/19/ablative-radiotherapy-controls-resistant-non-small-cell-lung-cancer-in-clinical-trial/) - An MSK team has shown that stereotactic body radiotherapy (SBRT) can keep oligoprogressive lung cancer under control more than 4 times longer than when patients receive standard care alone.
- [Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer](https://egfrcancer.org/2024/03/19/overcoming-drug-resistance-with-eai-432-an-allosteric-egfr-inhibitor-for-non-small-cell-lung-cancer/) - Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat NSCLC driven by EGFR mutations particularly the L858R mutation which is present in about one-third of NSCLC patients.
- [New Options for Initial Treatment of EGFR Mutant NSCLC](https://egfrcancer.org/2024/03/19/new-options-for-initial-treatment-of-egfr-mutant-nsclc/) - In this podcast, Dr. Stephen Liu discusses current 1st line treatment options for EGFR+ NSCLC, including new data from FLAURA2 and MARIPOSA trials.
- [Clinician Spotlight: Dr. Laura Petrillo](https://egfrcancer.org/2024/03/19/clinician-spotlight-dr-laura-petrillo/) - I recommend that newly-diagnosed patients find their peers because the support and education from other people dealing with something similar is invaluable.
- [Lung Cancer Advocacy Opportunities for Resisters and Their Caregivers/Family Members/Friends](https://egfrcancer.org/2024/03/19/lung-cancer-advocacy-opportunities-for-resisters-and-their-caregivers-family-members-friends/) - If you as a lung cancer patient/survivor, caregiver, family member or friend would like to take on advocacy work either politically or scientifically, there are free training and opportunities for all.
- [How Can Patients Drive Research](https://egfrcancer.org/2018/03/06/how-can-patients-drive-research/)
- [A Mix-and-Match Approach to Treating Non-Small-Cell Lung Cancer](https://egfrcancer.org/2018/05/01/a-mix-and-match-approach-to-treating-non-small-cell-lung-cancer/) - Lung Cancer: Antibiotics didn’t work, and her doctor called for more tests: a CT scan revealed a tumor the size of a fist in her right lung.
- [November Begins My Month of Thankfulness](https://egfrcancer.org/2018/11/13/november-begins-my-month-of-thankfulness/) - Community advocate Donna shares everything she's thankful for this November and how her lung cancer isn't holding her back from happiness.
- [J&J buys novel lung cancer drug from South Korea’s Yuhan](https://egfrcancer.org/2018/11/22/jj-buys-novel-lung-cancer-drug-from-south-koreas-yuhan-2/) - Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer.
- [Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors](https://egfrcancer.org/2018/11/22/overcoming-egfr-g724s-mediated-osimertinib-resistance-through-unique-binding-characteristics-of-second-generation-egfr-inhibitors-2/) - The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients.
- [PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS](https://egfrcancer.org/2018/11/22/patients-launch-new-study-to-shed-light-on-egfr-positive-lung-cancers/) - Scientists, physicians and patients collaborate to improve treatment for rare cancer.
- [Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer](https://egfrcancer.org/2019/01/04/cancer-research-uk-tests-first-of-its-kind-vaccine-to-treat-lung-cancer-2/) - A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC).
- [Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer](https://egfrcancer.org/2019/01/04/study-shows-key-enzyme-linked-to-therapy-resistance-in-deadly-lung-cancer/) - Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.
- [OncTalk 2018 - Local Therapies for Metastatic Lung Cancer - Who, What, Why, When and How?](https://egfrcancer.org/2019/01/05/onctalk-2018-local-therapies-for-metastatic-lung-cancer-who-what-why-when-and-how/) - GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast.
- [Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC](https://egfrcancer.org/2019/02/03/continuing-osimertinib-treatment-after-progression-prolongs-survival-benefit-in-nsclc/) - Patients who continued receiving osimertinib after their NSCLC had progressed demonstrated a prolonged benefit beyond the initial progression event.
- [A cancer researcher reflects on the evolution of lung cancer therapies](https://egfrcancer.org/2019/02/03/a-cancer-researcher-reflects-on-the-evolution-of-lung-cancer-therapies/) - Over the last two decades, scientific discoveries and new approaches have dramatically improved outcomes, greatly increasing life expectancy for some patients.
- [Overcoming Resistance to Targeted Therapies in EGFR-Positive Patients](https://egfrcancer.org/2019/02/03/overcoming-resistance-to-targeted-therapies-in-egfr-positive-patients/) - Dr. Piotrowska began studying biopsy and blood samples taken from patients before and after treatment with osimertinib.
- [Talking to Your Children About Cancer© ](https://egfrcancer.org/2019/03/14/talking-to-your-children-about-cancer/) - In talking with your children, how can you do it with love and wisdom.
- [Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon  ](https://egfrcancer.org/2019/03/14/novel-and-innovative-approach-to-monitoring-disease-progression-in-cancer-on-horizon/) - Currently available for research purposes only, the Signatera (RUO) is the first ctDNA assay custom-built for treatment monitoring and minimal residual disease assessment.
- [Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance](https://egfrcancer.org/2019/03/17/deep-dive-afatinibcetuximab-for-t790m-neg-patients-with-acquired-resistance/) - Cetuximab+afatinib inhibit EGFR pathway and has demonstrated synergistic potency for anti-tumor activity, and induced antibody-dependent cell cytotoxicity in patients.
- [Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR](https://egfrcancer.org/2019/03/17/overcoming-resistance-to-targeted-therapies-in-egfr-positive-patients-2/) - Case study of latest clinical data of brigatinib+cetuximab combo that has stabilized triple-mutant EGFR patient with concomitant T790M and C797S mutations.
- [Keeping the Romance Vital: Sexuality and Cancer © ](https://egfrcancer.org/2019/04/18/keeping-the-romance-vital-sexuality-and-cancer/) - Sexual healing from the blows of cancer treatment.
- [High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients](https://egfrcancer.org/2019/06/18/high-pd-l1-expression-correlates-with-primary-resistance-to-egfr-tkis-in-treatment-naive-advanced-egfr-mutant-lung-adenocarcinoma-patients/) - Relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma
- [Warning: Using Osimertinib After Immunotherapy](https://egfrcancer.org/2019/06/18/warning-using-osimertinib-after-immunotherapy/) - Latest research indicates immunotherapy followed by osimertinib resulted in serious immune related adverse events in some advanced lung cancer patients. 
- [It's Never Enough](https://egfrcancer.org/2019/06/22/its-never-enough/) - I remember thinking when I was first diagnosed that if I would be lucky enough to see my boys go to college, I would be satisfied with a life lived well.
- [1st Annual EGFR Resisters Research Summit - November 15-16, 2019 in Chicago](https://egfrcancer.org/2019/07/06/1st-annual-egfr-resisters-research-summit-november-15-16-2019-in-chicago/) - EGFR Resisters Research Summit is inviting Young Investigators (Junior Faculty or Fellows) in the EGFR lung cancer space to submit abstracts to us by 8/12/19.
- [Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow](https://egfrcancer.org/2019/07/06/video-next-generation-sequencing-for-egfr-mutant-lung-cancer-how-it-guides-treatment-today-tomorrow/) - Oncologist Dr. Josh Bauml presents "Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow.
- [Video: Intro to EGFR Mutation in Lung Cancer | Hope With Answers](https://egfrcancer.org/2019/07/17/video-intro-to-egfr-mutation-in-lung-cancer-hope-with-answers/) - Understand the EGFR mutation in lung cancer with Dr. Natasha Leighl of Toronto's Princess Margaret Hospital and patient and advocate Jill Feldman.
- [Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer](https://egfrcancer.org/2019/08/12/cumulative-antibiotic-use-significantly-decreases-efficacy-of-checkpoint-inhibitors-in-patients-with-advanced-cancer/) - Several studies suggest that antibiotic use may result in poorer outcomes for patients treated with immune checkpoint inhibitors.
- [Are BiTE Antibodies The Next Treatment for EGFR + NSCLC?](https://egfrcancer.org/2019/08/12/are-bite-antibodies-the-next-treatment-for-egfr-nsclc/) - While TKIs are the current standard treatment for EGFR+ advanced non-small cell lung cancer (NSCLC), BiTE antibodies are showing promise as a potential new treatment.
- [In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer](https://egfrcancer.org/2019/08/12/in-depth-overview-of-tyrosine-kinase-inhibitor-treatment-of-egfr-lung-cancer/) - Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve EGFR+ lung cancer survival.
- [How Patients Can Participate in EGFR Research (Video)](https://egfrcancer.org/2019/09/25/in-depth-overview-of-tyrosine-kinase-inhibitor-treatment-of-egfr-lung-cancer-2-2/) - Video on How Patients can Participate in EGFR Research: Conversation/Q&A with Dr. Pasi Janne, one of the world's foremost experts in EGFR lung cancer research.
- [Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity](https://egfrcancer.org/2019/09/25/hypofractionated-egfr-tyrosine-kinase-inhibitor-limits-tumor-relapse-through-triggering-innate-and-adaptive-immunity/) - Improved efficacy of hypoTKI EGFR TKI relative to HyperTKI in triggering antitumor T cell responses/preventing relapse in TKI-sensitive syngeneic murine tumor model through a mechanism involving the type I IFN and MyD88 signaling pathways.
- [CAR-T Tx Shifts into First Gear in Lung Cancer](https://egfrcancer.org/2019/09/25/car-t-tx-shifts-into-first-gear-in-lung-cancer/) - CAR-T cell therapy successfully rode the fast track in blood cancers; can it have an equally positive run in lung cancer?
- [Overcoming Targeted Therapy Resistance in NSCLC](https://egfrcancer.org/2019/11/08/overcoming-targeted-therapy-resistance-in-nsclc/) - Insight into EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to front-line targeted treatments and for progressive disease.
- [Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC](https://egfrcancer.org/2019/11/08/analyzing-best-practices-for-targeting-egfr-resistance-mutations-in-egfr-nsclc/) - Two abstracts from 2019 ASCO Annual Meeting analyzed potential combos with osimertinib and additional agents to overcome resistance mutations after progression.
- [New Data Challenge Current Standard in Treating EGFR+ Lung Cancer](https://egfrcancer.org/2019/11/08/new-data-challenge-current-standard-in-treating-egfr-lung-cancer/) - Just when we thought we were all set with EGFR, we have some disruptive information that challenges how we're going to treat patients with EGFR-mutated cancers.
- [Learnings from EGFR Resisters' Project Priority at IASLC 2019](https://egfrcancer.org/2019/11/08/learnings-from-egfr-resisters-project-priority-at-iaslc-2019/) - Demographics, treatment, and resistance data presented by EGFR Resisters co-founders on the psycho-social findings.
- [New Clinical Trials](https://egfrcancer.org/2019/11/08/learnings-from-egfr-resisters-project-priority-at-iaslc-2019-2/) - Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Phase I trial with progression on osimertinib. Consists of osimertinib with a parp inhibitor, niraparib.
- [EGFR Resister Co-Founder Featured on The Today Show for Lung Cancer Awareness Month](https://egfrcancer.org/2019/12/20/egfr-resister-co-founder-featured-on-the-today-show-for-lung-cancer-awareness-month/) - Jill Feldman, an EGFR Resisters co-founder was interviewed on the Today Show regarding Lung Cancer Awareness Month.
- [Project PRIORITY: Why it matters to the EGFR-positive lung cancer community](https://egfrcancer.org/2019/12/20/project-priority-why-it-matters-to-the-egfr-positive-lung-cancer-community/) - Project PRIORITY is a collaboration between LUNGevity Foundation and the EGFR Resisters to understand unmet needs of the EGFR+ lung cancer community. 
- [Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers](https://egfrcancer.org/2020/01/18/dana-farber-cancer-institute-to-establish-chen-huang-center-for-egfr-mutant-lung-cancers/) - $5 million gift to support research and care of epidermal growth factor receptor (EGFR) mutant lung cancers
- [Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases](https://egfrcancer.org/2020/01/18/osimertinib-promising-for-egfr-mutant-nsclc-with-leptomeningeal-metastases/) - Patients with EGFR+ non-small-cell lung cancer and leptomeningeal metastases respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest.
- [Revisiting Chemo in EGFR-Mutant NSCLC](https://egfrcancer.org/2020/01/18/revisiting-chemo-in-egfr-mutant-nsclc/) - Significant improvement with chemo in PFS, OS versus EGFR inhibitor monotherapy
- [Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC](https://egfrcancer.org/2020/01/18/bridge-biotherapeutics-files-investigational-new-drug-application-for-bbt-176-an-egfr-tki-for-nsclc/) - ThIs targeted cancer therapy showed a potential of activity against EGFR C797S mutation in pre-clinical studies; first-in-human study initiated 2020.
- [Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC](https://egfrcancer.org/2020/01/18/lazertinib-shows-promising-antitumor-activity-in-patients-with-egfr-nsclc-2/) - With first- and second-generation EGFR TKI resistance in patients with EGFR+ NSCLC, lazertinib (YH25448), an irreversible, third-generation, mutant-selective TKI is being explored.
- [Scientists Reveal How Lung Cancer Cancer Cells Avoid Death from Targeted Drugs](https://egfrcancer.org/2020/03/04/scientists-reveal-how-lung-cancer-cancer-cells-avoid-death-from-targeted-drugs/) - Scientists say they have discovered a mechanism within lung cancer cells that enables the cells to lie dormant and avoid destruction by the cancer drugs.
- [FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC](https://egfrcancer.org/2020/03/04/fda-schedules-odac-meeting-on-ramucirumab-erlotinib-in-frontline-egfr-nsclc/) - ODAC hearing February 26, 2020, to discuss supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use with erlotinib (Tarceva) in frontline treatment for metastatic NSCLC with EGFR Ex19del or Ex21 substitution mutations.
- [FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC](https://egfrcancer.org/2020/03/04/fda-grants-fast-track-designation-to-oncoprex-combination-for-nsclc/) - Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA for EGFR+ NSCLC lung cancer that progressed after osimertinib.
- [Scientists link common immune cell to failure of checkpoint inhibitors in lung cancer](https://egfrcancer.org/2020/03/04/scientists-link-common-immune-cell-to-failure-of-checkpoint-inhibitors-in-lung-cancer/) - Predicting if immunotherapy can help a given patient and sorting out by cellular signature may help doctors avoid toxicities in people unlikely to benefit from the drug
- [Keeping Safe and Sane in Midst of Pandemic](https://egfrcancer.org/2020/03/19/keeping-safe-and-sane-in-midst-of-pandemic/) - A compilation of info from trusted experts regarding staying safe and sane amid coronavirus
- [T-cell stimulation could be used to target cancers with common TP53 gene mutations](https://egfrcancer.org/2020/04/01/t-cell-stimulation-could-be-used-to-target-cancers-with-common-tp53-gene-mutations/) - Circulating lymphocytes can be stimulated in the laboratory to generate cells that can recognize TP53 gene mutations.
- [FDA Grants Priority Review to Capmatinib in METex14+ NSCLC](https://egfrcancer.org/2020/04/01/fda-grants-priority-review-to-capmatinib-in-metex14-nsclc/) - The FDA has granted a priority review designation for capmatinib for treatment of newly-diagnosed and previously-treated patients with MET exon14 skipping NCSLC
- [Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer](https://egfrcancer.org/2020/04/01/tumor-analyses-reveal-squamous-transformation-and-off-target-alterations-as-early-resistance-mechanisms-to-first-line-osimertinib-in-egfr-mutant-lung-cancer/) - Histologic transformation and other off-target molecular alterations are frequent early emerging resistance mechanisms to osimertinib.
- [DOUBLE JEOPARDY: Cancer and COVID-19](https://egfrcancer.org/2020/04/08/double-jeopardy-cancer-and-covid-19/) - I have been asked to address the emotional impact for those of you dealing with cancer and also fearing COVID-19. What a huge task it is to cope with yet another threat to your lives!
- [Research Aims to Augment OS Benefit With Osimertinib in EGFR+ NSCLC](https://egfrcancer.org/2020/04/08/research-aims-to-augment-os-benefit-with-osimertinib-in-egfr-nsclc/) - The current treatment landscape of EGFR-mutant NSCLC and the research being done to define chemotherapy-sparing combinations for patients who progress on frontline TKIs.
- [FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer](https://egfrcancer.org/2020/04/08/research-aims-to-augment-os-benefit-with-osimertinib-in-egfr-nsclc-2/) - JNJ-6372 has been approved for people whose metastatic NSCLC continues to grow either during or after receiving platinum-based chemotherapy.
- [Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia](https://egfrcancer.org/2020/04/08/treating-patients-with-met-alterations-a-qa-with-dr-ravi-salgia/) - Dr. Salgia discusses current and future directions in the treatment of patients with lung cancer with MET alterations.
- [Cause of Resistance to 3rd-Gen EGFR-TKIs Varied in T790M-Mutated NSCLC](https://egfrcancer.org/2020/04/08/cause-of-resistance-to-3rd-gen-egfr-tkis-varied-in-t790m-mutated-nsclc/) - Targeted sequencing of patients with acquired resistance to third-gen EGFR TKIs for EGFR T790M-mutant NSCLC revealed that resistance is associated with diverse pathways.
- [Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research](https://egfrcancer.org/2020/04/08/building-on-immunotherapy-preventing-acquired-resistance-are-next-steps-in-lung-cancer-research/) - Dr. David Carbone discusses advances in immunotherapy and targeted therapy in NSCLC and ongoing research efforts focused on acquired resistance to available therapies.
- [Circulating Tumor DNA Testing—Liquid Biopsy of a Cancer](https://egfrcancer.org/2020/04/08/circulating-tumor-dna-testing-liquid-biopsy-of-a-cancer/) - It is now possible to look for a wide range of cancer-associated variations in the ctDNA in a patient’s blood sample.
- [ASCO 2020 Poster Walk: Lung Cancer Highlights](https://egfrcancer.org/2020/06/12/circulating-tumor-dna-testing-liquid-biopsy-of-a-cancer-2/) - Webcast: Experts highlight and interpret lung cancer research studies from ASCO 2020.
- [Webcast: Myths vs Facts in EGFRm Lung Cancer](https://egfrcancer.org/2020/06/12/webcast-myths-vs-facts-in-egfrm-lung-cancer/) - Webcast: Lung cancer experts discuss the latest treatments in lung cancer.
- [How Do I Handle This Cancer Part 1](https://egfrcancer.org/2020/06/12/webcast-myths-vs-facts-in-egfrm-lung-cancer-2/) - When a diagnosis of cancer lands with a thud in people's lives, treatment and uncertainty strain all the ways they know how to cope.
- [Almonertinib Induces Response in EGFR T790M-Positive NSCLC With CNS Metastases](https://egfrcancer.org/2020/06/12/almonertinib-induces-response-in-egfr-t790m-positive-nsclc-with-cns-metastases/) - The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile.
- [Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC](https://egfrcancer.org/2020/06/12/almonertinib-induces-response-in-egfr-t790m-positive-nsclc-with-cns-metastases-2/) - This video with lung cancer expert, Dr. David Carbone, discusses acquired resistance to osimertinib in NSCLC
- [Winship treats first lung cancer patient with T-cell receptor therapy](https://egfrcancer.org/2020/06/12/almonertinib-induces-response-in-egfr-t790m-positive-nsclc-with-cns-metastases-2-2/) - The first lung cancer patient to be treated with a new type of immunotherapy involving the re-engineering of a patient's T cells took place at Winship Cancer Institute of Emory University on May 7, 2020.
- [How Do I Handle This Cancer Part 2](https://egfrcancer.org/2020/09/18/how-do-i-handle-this-cancer-part-2/) - This is the second part of a four-part series on how people cope with cancer.
- [First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer](https://egfrcancer.org/2020/09/18/first-line-osimertinib-bevacizumab-for-metastatic-egfr-mutant-lung-cancer/) - In a phase II clinical trial, it was found that the combination of first-line osimertinib and bevacizumab resulted in a high rate of 1-year PFS in metastatic EGFR+ lung cancer patients.
- [Video: Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?](https://egfrcancer.org/2020/09/18/video-progress-in-the-management-of-egfr-mutant-nsclc-in-2020-where-are-we-now/) - Dr. Roy Herbst addresses the question: Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?
- [SRS for Brain Metastases in Small Cell Lung Cancer?](https://egfrcancer.org/2020/09/18/srs-for-brain-metastases-in-small-cell-lung-cancer/) - Retrospective data show similar outcomes to first-line WBRT
- [Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC](https://egfrcancer.org/2020/09/18/capmatinib-approved-in-japan-for-metex14-altered-advanced-nsclc/) - The Japanese Ministry of Health, Labor, and Welfare has approved capmatinib for patients with MET exon 14 skipping mutation–positive advanced and/or recurrent unresectable nsclc.
- [FDA Accelerates Approval of Lurbinectedin in Metastatic SCLC](https://egfrcancer.org/2020/09/18/fda-accelerates-approval-of-lurbinectedin-in-metastatic-sclc/) - The FDA had granted accelerated approval to lurbinectedin (Zepzelca) for metastatic small cell lung cancer after progression on or after platinum-based chemotherapy.
- [How Do I Handle This Cancer Part 3](https://egfrcancer.org/2020/09/18/how-do-i-handle-this-cancer-part-3/) - This is the third part of a four-part series on how people cope with cancer.
- [Treatment Landscape Expands for EGFR-Mutated Non–Small Cell Lung Cancer](https://egfrcancer.org/2020/09/18/almonertinib-induces-response-in-egfr-t790m-positive-nsclc-with-cns-metastases-2-2-2/) - Balazs Halmos, MD, MS, discusses the current treatment landscape of EGFR-mutant NSCLC and how this space is evolving based on recent clinical trials.
- [Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series](https://egfrcancer.org/2020/09/18/stereotactic-irradiation-of-non-small-cell-lung-cancer-brain-metastases-evaluation-of-local-and-cerebral-control-in-a-large-series/) - A retrospective analysis in consecutively treated patients who underwent SRT alone for brain metastases from non-small cell lung cancer (NSCLC).
- [Knockdown of IKKβ Inhibits Tumor Development in a Leptomeningeal Metastasis Mouse Model and Proliferation of Lung Cancer Cells](https://egfrcancer.org/2020/09/18/stereotactic-irradiation-of-non-small-cell-lung-cancer-brain-metastases-evaluation-of-local-and-cerebral-control-in-a-large-series-2/) - Blocking the NF-κB signaling pathway by IKKβ knockdown in Lewis Lung Cancer (LLC) cells inhibited tumor growth in the leptomeningeal metastasis (LM) mouse model.
- [How Do I Handle This Cancer Part 4](https://egfrcancer.org/2020/10/16/how-do-i-handle-this-cancer-part-4/) - This is the fourth part of a six-part series on how people cope with cancer.
- [Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer](https://egfrcancer.org/2020/10/16/indications-continue-to-expand-for-egfr-targeted-therapies-in-lung-cancer/) - Earlier TKI resistance is growing, and NsCLC molecular heterogeneity is prompting is generating treatment combinations/strategies to more precisely tailor treatments to patients.
- [Non Small Cell Lung Cancer EGFR Mutation Treatment](https://egfrcancer.org/2020/10/16/non-small-cell-lung-cancer-egfr-mutation-treatment/) - Two lung cancer experts explain two studies that provide new treatment options for EGFR lung cancer patients.
- [Homing in on Brain Mets’ Distinct Alterations Offers Hope for Precision Medicine Approach](https://egfrcancer.org/2020/10/16/homing-in-on-brain-mets-distinct-alterations-offers-hope-for-precision-medicine-approach/) - Targeted therapies directed at genetic alterations specific to brain mets is emerging as a viable precision medicine approach.
- [Radiosurgery Improves Clinical Outcomes in Brain Metastasis Treatment](https://egfrcancer.org/2020/10/16/radiosurgery-improves-clinical-outcomes-in-brain-metastasis-treatment/) - A pooled analysis of 2 randomized clinical trials: how clinical outcomes and quality of life were impacted with sbrt vs wbr in patients with brain mets.
- [Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy](https://egfrcancer.org/2020/10/16/talking-kras-targeted-therapy-in-nsclc-with-dr-levy/) - Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.
- [FDA Grants Priority Review to Trilaciclib in Chemotherapy-Treated Small Cell Lung Cancer](https://egfrcancer.org/2020/10/16/fda-grants-priority-review-to-trilaciclib-in-chemotherapy-treated-small-cell-lung-cancer/) - The FDA has granted Priority Review to the New Drug Application for trilaciclib for the treatment of patients with SCLC who are receiving chemotherapy.
- [FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC](https://egfrcancer.org/2020/10/16/fda-grants-priority-review-to-tepotinib-for-metex14-altered-metastatic-nsclc/) - The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic NSCLC with a MET exon 14 (METex14) skipping mutation.
- [Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer](https://egfrcancer.org/2020/10/16/dr-pennell-on-the-evolution-of-targeting-her2-in-lung-cancer/) - Video: Nathan A. Pennell, MD, PhD discusses the evolution of targeting HER2 in lung cancer.
- [How Do I Handle This Cancer Part 5](https://egfrcancer.org/2020/10/16/how-do-i-handle-this-cancer-part-5/) - This is the fifth part of a six-part series on how people cope with cancer.
- [First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC](https://egfrcancer.org/2020/10/16/first-line-apatinib-gefitinib-combo-shows-significant-benefit-for-egfr-mutant-nsclc/) - Combination of apatinib and gefitinib in the 1st line treatment of patients with advanced EGFR NSCLC demonstrated superior progression-free survival.
- [EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC](https://egfrcancer.org/2020/10/16/first-line-apatinib-gefitinib-combo-shows-significant-benefit-for-egfr-mutant-nsclc-2/) - The combination of amivantamab/lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib-resistant advanced EGFR+ NSCLC patients.
- [Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer](https://egfrcancer.org/2020/10/16/osimertinib-bevacizumab-combination-fails-to-prolong-pfs-in-egfr-t790m-lung-cancer/) - The combination of osimertinib and bevacizumab did not prolong PFS in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone.
- [BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models](https://egfrcancer.org/2020/10/16/blu-945-elicits-robust-clinical-activity-in-preclinical-egfr-lung-cancer-models/) - BLU-945 is a 4th generation EGFR TKI that potently inhibits triple-mutant EGFR with either activated L858R or exon 19 deletion mutations, plus acquired T790M and C797S mutations.
- [Drug Active in 'Undruggable' KRAS-Mutant NSCLC](https://egfrcancer.org/2020/10/16/drug-active-in-undruggable-kras-mutant-nsclc/) - Sotorasib, a small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with NSCLC.
- [First Drug for MET+ NSCLC Shows High Response Rates](https://egfrcancer.org/2020/10/16/first-drug-for-met-nsclc-shows-high-response-rates/) - The first targeted therapy for patients with advanced NSCLC harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses.
- [Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC](https://egfrcancer.org/2020/10/16/dr-rizvi-on-the-utility-of-trastuzumab-deruxtecan-in-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [2020 Annual EGFR Resisters Research Summit Wrap Up](https://egfrcancer.org/2020/10/22/2020-annual-egfr-resisters-research-summit-wrap-up/) - Dr. Josh Bauml, along with EGFR Resisters founders Ivy Elkins, Jill Feldman, and Ildiko Medve, summarize the highlights of this research summmit on lung cancer.
- [2020 Annual EGFR Resisters Research Summit Wrap Up](https://egfrcancer.org/2020/11/11/2020-annual-egfr-resisters-research-summit-wrap-up-2/) - The first targeted therapy for patients with advanced NSCLC harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses.
- [How Do I Handle This Cancer Part 6](https://egfrcancer.org/2021/01/06/how-do-i-handle-this-cancer-part-6/) - This is the fifth part of a six-part series on how people cope with cancer.
- [Targeted Radiation Wins for Treating 'Numerous' Brain Metastases ](https://egfrcancer.org/2021/01/06/first-drug-for-met-nsclc-shows-high-response-rates-2/) - The first targeted therapy for patients with advanced NSCLC harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses.
- [ASCO Lung Cancer Roundtable - NSCLC - The SINDAS Trial: Addition of SBRT to a Systemic TKI for EGFR](https://egfrcancer.org/2021/01/06/first-drug-for-met-nsclc-shows-high-response-rates-2-2/) - The first targeted therapy for patients with advanced NSCLC harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses.
- [Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC](https://egfrcancer.org/2021/01/06/identifying-treating-resistance-to-tkis-are-next-step-in-egfr-nsclc-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Podcast: EGFR Mutation Patient Progression and Next Steps from cancerGRACE](https://egfrcancer.org/2021/01/06/podcast-egfr-mutation-patient-progression-and-next-steps-from-cancergrace/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Targeted Therapy Research Booms in Biomarker-Positive NSCLC](https://egfrcancer.org/2021/01/06/targeted-therapy-research-booms-in-biomarker-positive-nsclc-3/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer](https://egfrcancer.org/2021/01/06/new-study-shows-shp2-inhibition-overcomes-multiple-therapeutic-resistance-mechanisms-in-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer](https://egfrcancer.org/2021/01/06/oncogene-specific-advocacy-groups-bring-a-patient-centric-perspective-to-studies-of-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [How Do I Handle This Cancer Part 7](https://egfrcancer.org/2021/01/06/how-do-i-handle-this-cancer-part-7/) - This is the fifth part of a six-part series on how people cope with cancer.
- [Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC](https://egfrcancer.org/2021/01/06/targeted-therapy-research-booms-in-biomarker-positive-nsclc-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [MET Target Excites Treatment Paradigm for Patients With Lung Cancer](https://egfrcancer.org/2021/01/06/targeted-therapy-research-booms-in-biomarker-positive-nsclc-2-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC](https://egfrcancer.org/2021/01/06/targeted-therapy-research-booms-in-biomarker-positive-nsclc-2-2-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Targeting mutations that drive lung cancer](https://egfrcancer.org/2021/01/06/targeting-mutations-that-drive-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Amivantamab Plus Lazertinib Combo Shows Good Results in EGFR+ NSCLC](https://egfrcancer.org/2021/01/06/targeted-therapy-research-booms-in-biomarker-positive-nsclc-2-2-3/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Bone Pain is a Common Side Effect of Cancer & Its Treatment](https://egfrcancer.org/2021/01/06/bone-pain-is-a-common-side-effect-of-cancer-its-treatment/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer](https://egfrcancer.org/2021/01/06/inhibitors-of-met-ret-and-trk-now-enjoy-standard-of-care-status-in-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC](https://egfrcancer.org/2021/01/06/neratinib-shows-early-activity-in-egfr-exon-18-mutated-metastatic-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform..](https://egfrcancer.org/2021/01/06/new-clinical-trial-olaparib-lynparza-plus-durvalumab-imfinzi-in-egfr-mutated-adenocarcinomas-that-transform-to-small-cell-lung-cancer-sclc-and-other-neuroendocrine-tumors/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Frontline Regimens Explored for EGFR-Mutated NSCLC](https://egfrcancer.org/2021/01/21/frontline-regimens-explored-for-egfr-mutated-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC](https://egfrcancer.org/2021/01/21/manochakian-calls-for-repeat-genomic-testing-upon-osimertinib-progression-in-egfr-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC](https://egfrcancer.org/2021/01/21/osimertinib-improves-overall-survival-in-patients-with-egfr-mutated-nsclc-with-leptomeningeal-metastases-regardless-of-t790m-mutational-status/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine](https://egfrcancer.org/2021/01/21/increased-attention-on-testing-for-oncogenic-drivers-in-nsclc-advances-the-promise-of-precision-medicine/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy](https://egfrcancer.org/2021/01/21/genetic-heterogeneity-of-met-aberrant-non-small-cell-lung-cancer-and-its-impact-on-the-outcome-of-immunotherapy/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Enriching Responses With Targeted Therapy in NSCLC](https://egfrcancer.org/2021/01/21/manochakian-calls-for-repeat-genomic-testing-upon-osimertinib-progression-in-egfr-nsclc-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Ask the Experts: Progression and Resistance](https://egfrcancer.org/2021/01/21/ask-the-experts-progression-and-resistance/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Perception of Palliative Care and Prognostic Awareness of Lung Cancer Treatment in an Oncogene-Driven Lung Cancer Community](https://egfrcancer.org/2021/01/31/perception-of-palliative-care-and-prognostic-awareness-of-lung-cancer-treatment-in-an-oncogene-driven-lung-cancer-community/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions](https://egfrcancer.org/2021/03/06/diversifying-clinical-trial-inclusion-criteria-currrent-challenges-and-potential-solutions/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC](https://egfrcancer.org/2021/03/06/patritumab-deruxtecan-shows-early-activity-in-metastatic-egfr-mutant-nsclc/) - With first- and second-generation EGFR TKI resistance in patients with EGFR+ NSCLC, lazertinib (YH25448), an irreversible, third-generation, mutant-selective TKI is being explored.
- [Multicenter Analysis of Mechanisms of Resistance to Osimertinib in EGFR Mutated NSCLC: An ATOMIC Registry Study](https://egfrcancer.org/2021/03/07/multicenter-analysis-of-mechanisms-of-resistance/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Options for Patients with NSCLC That Has Progressed After Osimertinib](https://egfrcancer.org/2021/03/17/options-for-patients-with-nsclc-that-has-progressed-after-osimertinib/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC](https://egfrcancer.org/2021/03/17/osimertinib-bevacizumab-improves-orr-but-fails-to-prolong-pfs-in-egfr-t790m-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Chemoimmunotherapy Continues to Display Survival Benefits in Small Cell Lung Cancer](https://egfrcancer.org/2021/03/22/chemoimmunotherapy-continues-to-display-survival-benefits-in-small-cell-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Navigating Nuances in Early and Metastatic Lung Cancer Treatment](https://egfrcancer.org/2021/03/22/navigating-nuances-in-early-and-metastatic-lung-cancer-treatment/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer](https://egfrcancer.org/2021/03/22/tkis-set-the-stage-for-treatment-in-her2-mutant-lung-cancer-but-may-be-eclipsed-by-adcs/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward](https://egfrcancer.org/2021/03/22/new-designations-and-efficacy-demonstrations-push-the-egfr-nsclc-paradigm-forward/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase](https://egfrcancer.org/2021/03/22/egfr-tki-combination-therapies-c797s-mek-aurora-kinase/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Hope, That Double-Edged Sword](https://egfrcancer.org/2021/03/22/hope-that-double-edged-sword/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC](https://egfrcancer.org/2021/03/22/osimertinib-penetrates-blood-brain-barrier-and-decreases-metastasis-in-egfr-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Winners of the 2nd EGFR Resisters Research Summit](https://egfrcancer.org/2021/06/19/winners-egfr-research-summit/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award](https://egfrcancer.org/2021/06/19/egfr-resisters-and-lungevity-foundation-partner-on-lung-cancer-research-award/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Ask the Experts: Progression and Resistance “I Have Another Oncogene Driver!”](https://egfrcancer.org/2021/06/19/ask-the-experts-progression-and-resistance-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [EGFR Resisters Self-Funded Research Projects for 2021](https://egfrcancer.org/2021/06/19/egfr-resisters-self-funded-research-projects-for-2021/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [We Honor Allen Lee, Co-Founder of EGFR Resisters](https://egfrcancer.org/2021/06/19/we-honor-allen-lee-co-founder-of-egfr-resisters/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [WILL I BE NEXT? COPING WITH FEAR WHEN FRIENDS DIE](https://egfrcancer.org/2021/06/19/cancer-coping-fear-friends-die/) - When people, even online friends we have not met in person, die of the same disease we are struggling with, grief and anxiety collide within us. The low hum of fear which follows us like a shadow becomes a shout from within that feels beyond consolation.
- [Exploring EGFR Mutations in Lung Cancer: Key Diagnostic & Management Strategies](https://egfrcancer.org/2021/06/19/exploring-egfr-mutations-in-lung-cancer-key-diagnostic-management-strategies/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib Continues to Enhance Outcomes in EGFR+ NSCLC](https://egfrcancer.org/2021/06/19/osimertinib-continues-to-enhance-outcomes-in-egfr-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Levy Lauds Biomarker-Driven Data in Lung Cancer](https://egfrcancer.org/2021/06/19/levy-lauds-biomarker-driven-data-in-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Immunotherapy in non-small cell lung cancer harbouring driver mutations](https://egfrcancer.org/2021/06/19/immunotherapy-in-non-small-cell-lung-cancer-harbouring-driver-mutations/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer](https://egfrcancer.org/2021/06/19/dr-porter-on-potential-sequencing-with-adcs-and-tkis-in-her2-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC](https://egfrcancer.org/2021/06/19/patritumab-deruxtecan-under-exploration-in-phase-2-herthena-lung01-trial-for-egfr-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Emerging Agents and Future of Small Cell Lung Cancer (SCLC)](https://egfrcancer.org/2021/06/19/emerging-agents-and-future-of-small-cell-lung-cancer-sclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC](https://egfrcancer.org/2021/06/20/telisotuzumab-vedotin-demonstrates-efficacy-and-tolerability-in-previously-treated-c-met-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [The Wisdom of Mortality](https://egfrcancer.org/2021/06/20/the-wisdom-of-mortality/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Investigators Launch Epidemiology Study in Younger Patients With NSCLC](https://egfrcancer.org/2021/06/20/investigators-launch-epidemiology-study-in-younger-patients-with-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Overcoming therapy resistance in EGFR-mutant lung cancer](https://egfrcancer.org/2021/06/20/overcoming-therapy-resistance-in-egfr-mutant-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib Combos Under Evaluation to Improve Outcomes, Combat Resistance in EGFR+ NSCLC](https://egfrcancer.org/2021/06/20/osimertinib-combos-under-evaluation-to-improve-outcomes-combat-resistance-in-egfr-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [The SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC](https://egfrcancer.org/2021/06/21/the-sindas-trial-the-addition-of-sbrt-to-a-systemic-egfr-inhibitor-tki-in-egfr-positive-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Understanding Histological Transformation in EGFR-positive NSCLC](https://egfrcancer.org/2021/06/21/understanding-histological-transformation-in-egfr-positive-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [FDA Grants Priority Review to Mobocertinib for Advanced EGFR Exon 20–Mutant NSCLC](https://egfrcancer.org/2021/06/21/fda-grants-priority-review-to-mobocertinib-for-advanced-egfr-exon-20-mutant-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [LUNGevity's HOPE Summit: Ivy Elkin's Journey to Research Advocacy](https://egfrcancer.org/2021/06/21/lungevitys-hope-summit-ivy-elkins-journey-to-research-advocacy/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Ask the Experts: Progression. Testing, Common Mechanisms of EGFR Resistance, & Treatment Strategies](https://egfrcancer.org/2021/06/21/ask-the-experts-progression-and-resistance-2-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Still Living With Uncertainty](https://egfrcancer.org/2021/06/21/still-living-with-uncertainty/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer](https://egfrcancer.org/2021/06/21/fda-grants-priority-review-to-mobocertinib-for-advanced-egfr-exon-20-mutant-nsclc-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC](https://egfrcancer.org/2021/06/21/oleclumab-plus-osimertinib-show-early-activity-and-tolerability-egfr-mutant-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib](https://egfrcancer.org/2021/06/21/heterogeneity-of-acquired-resistance-mechanisms-to-osimertinib-and-savolitinib/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Treatment Options for Metastatic NSCLC](https://egfrcancer.org/2021/06/21/treatment-options-for-metastatic-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Immunotherapy in non-small cell lung cancer harbouring driver mutations](https://egfrcancer.org/2021/06/21/immunotherapy-in-non-small-cell-lung-cancer-harbouring-driver-mutations-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [EGFR-Mutated Metastatic NSCLC: Evolving Practice Standards and Opportunities for Improving Outcomes](https://egfrcancer.org/2021/06/24/egfr-mutated-metastatic-nsclc-evolving-practice-standards-and-opportunities-for-improving-outcomes/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report](https://egfrcancer.org/2021/06/24/durable-response-of-leptomeningeal-disease-with-osimertinib-and-pemetrexed-in-egfr-mutated-metastatic-nsclc-a-case-report/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [New EGFR Resisters Multi-Year Research Partnership with Lung Cancer Research Foundation (LCRF)](https://egfrcancer.org/2021/06/24/new-egfr-resisters-multi-year-research-partnership-with-lung-cancer-research-foundation-lcrf/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC](https://egfrcancer.org/2021/09/06/patritumab-deruxtecan-shows-promise-for-egfr-inhibitor-resistant-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC](https://egfrcancer.org/2021/09/06/dr-spira-on-the-updated-results-of-the-chrysalis-trial-in-egfr-mutant-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Aumolertinib vs Gefitinib for NSCLC EGFR exon 19 del or L858R mutations](https://egfrcancer.org/2021/09/06/randomized-phase-iii-trial-of-aumolertinib-vs-gefitinib-as-1st-line-treatment-for-egfr-exon-19-del-or-l858r-mutations/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Talking to Your Children About Cancer](https://egfrcancer.org/2021/09/06/talking-to-your-children-about-cancer-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC](https://egfrcancer.org/2021/09/06/clinical-challenge-optimal-therapies-for-rare-egfr-mutations-in-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response](https://egfrcancer.org/2021/09/06/amivantamab-in-combination-with-lazertinib-for-the-treatment-of-osimertinib-relapsed-chemotherapy-naive-egfr-mutant-egfrm-non-small-cell-lung-cancer-nsclc-and-potential-biomarkers-for-response/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Experts Break Down Exciting Breakthroughs in NSCLC](https://egfrcancer.org/2021/09/06/experts-break-down-exciting-breakthroughs-in-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Clinical Trial Finder Medifind: Tailored to EGFR Lung Cancer Patients](https://egfrcancer.org/2021/09/07/clinical-trial-finder-medifind-tailored-to-egfr-lung-cancer-patient/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [The CHRYSALIS Study: Phase 1 Clinical Trial Is Open for Enrollment](https://egfrcancer.org/2021/09/07/the-chrysalis-study-phase-1-clinical-trial-is-open-for-enrollment/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Landmark Study Underscores Lung Cancer Differences in Young Adults](https://egfrcancer.org/2021/09/07/landmark-study-underscores-lung-cancer-differences-in-young-adults/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance](https://egfrcancer.org/2021/09/07/eatment-strategies-relies-on-identification-of-resistance/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC](https://egfrcancer.org/2021/09/07/4-novel-drug-classes-demonstrate-early-promise-for-egfr-mutated-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC](https://egfrcancer.org/2021/09/07/predicting-the-future-of-overcoming-egfr-resistance-mechanisms-in-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Amivantamab & Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC](https://egfrcancer.org/2021/09/07/amivantamab-lazertinib-combination-may-overcome-osimertinib-resistance-in-patients-with-egfr-positive-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Efficacy and Safety of Patritumab Deruxtecan in EGFR Mutated NSCLC Resistant to EGFR TKI Therapy](https://egfrcancer.org/2021/09/07/efficacy-and-safety-of-patritumab-deruxtecan-in-egfr-mutated-nsclc-resistant-to-egfr-tki-therapy/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out](https://egfrcancer.org/2021/09/07/osimertinib-combinations-as-second-line-treatment-in-non-small-cell-lung-cancer-the-jurys-still-out/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC](https://egfrcancer.org/2021/09/07/oleclumab-plus-osimertinib-show-early-activity-and-tolerability-egfr-mutant-nsclc-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Immunotherapy Resistance in Non-Small Cell Lung Cancer: A Rubik’s Cube to Assemble](https://egfrcancer.org/2021/09/07/oleclumab-plus-osimertinib-show-early-activity-and-tolerability-egfr-mutant-nsclc-2-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [The White Ribbon Project: It's Time to Change the Lung Cancer Story](https://egfrcancer.org/2021/11/10/the-white-ribbon-project-its-time-to-change-the-lung-cancer-story/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation](https://egfrcancer.org/2021/11/10/brain-metastases-in-egfr-and-alk-positive-nsclc-outcomes-of-central-nervous-system-penetrant-tyrosine-kinase-inhibitors-alone-versus-in-combination-with-radiation/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Video: Dr. Carbone on Why Biomarker and Genomic Testing Matters](https://egfrcancer.org/2021/11/10/video-dr-carbone-on-why-biomarker-and-genomic-testing-matters/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [ChemoImmunotherapy or No ChemoImmunotherapy After Progression on Tagrisso?](https://egfrcancer.org/2021/11/10/chemoimmunotherapy-or-no-chemoimmunotherapy-after-progression-on-tagrisso/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Variant of NSCLC vs EGFR Mutations](https://egfrcancer.org/2021/11/10/variant-of-nsclc-vs-egfr-mutations/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [BLU-945 Clinical Trial Is Open for Triple Mutant EGFR](https://egfrcancer.org/2021/11/10/blu-945-clinical-trial-is-open-for-triple-mutant-egfr/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Moving MET into the clinic: Latest evidence for MET inhibitors in NSCLC](https://egfrcancer.org/2021/11/10/moving-met-into-the-clinic-latest-evidence-for-met-inhibitors-in-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Emerging Agents and Future of Small Cell Lung Cancer](https://egfrcancer.org/2021/11/10/emerging-agents-and-future-of-small-cell-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Amivantamab with lazertinib for patients with chemotherapy-naïve NSCLC with EGFR mutations who have experienced relapse on or after osimertinib therapy](https://egfrcancer.org/2021/11/10/emerging-agents-and-future-of-small-cell-lung-cancer-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Activity of patritumab deruxtecan in patients with EGFR inhibitor-resistant NSCLC with EGFR mutations](https://egfrcancer.org/2021/11/10/emerging-agents-and-future-of-small-cell-lung-cancer-2-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research](https://egfrcancer.org/2021/11/10/how-oncogene-driven-patient-groups-are-mobilizing-the-global-community-to-drive-research/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Highlights in Lung Cancer From ESMO 2021](https://egfrcancer.org/2021/11/10/highlights-in-lung-cancer-from-esmo-2021/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Words Matter](https://egfrcancer.org/2021/11/11/words-matter/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Treatment Patterns in Patients With EGFR-Positive Lung Cancer: A Real-World Patient Report](https://egfrcancer.org/2021/11/11/treatment-patterns-in-patients-with-egfr-positive-lung-cancer-a-real-world-patient-report/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Phase I Study of DZD9008 in EGFR Exon 20 HER2 NSCLC](https://egfrcancer.org/2021/11/11/treatment-patterns-in-patients-with-egfr-positive-lung-cancer-a-real-world-patient-report-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Positive early clinical results for amivantamab plus lazertinib in NSCLC](https://egfrcancer.org/2021/11/11/positive-early-clinical-results-for-amivantamab-plus-lazertinib-in-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [TROPION-PanTumor01 Trial With Datopotamab Deruxtecan (Dato-Dxd or DS-1062a)](https://egfrcancer.org/2021/11/11/tropion-pantumor01-trial-with-datopotamab-deruxtecan-dato-dxd-or-ds-1062a/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Testing Need for HER2 Mutations Routinely in NSCLC](https://egfrcancer.org/2021/11/11/tropion-pantumor01-trial-with-datopotamab-deruxtecan-dato-dxd-or-ds-1062a-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC](https://egfrcancer.org/2021/11/11/tropion-pantumor01-trial-with-datopotamab-deruxtecan-dato-dxd-or-ds-1062a-2-2/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Osimertinib + Bevacizumab for EGFR+ NSCLC: Another negative trial](https://egfrcancer.org/2021/11/11/osimertinib-bevacizumab-for-egfr-nsclc-another-negative-trial/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Structure-based classification predicts drug response in EGFR-mutant NSCLC](https://egfrcancer.org/2021/11/11/structure-based-classification-predicts-drug-response-in-egfr-mutant-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Lauren Byers, MD, on Personalized Therapy in Small-Cell Lung Cancer](https://egfrcancer.org/2021/11/11/lauren-byers-md-on-personalized-therapy-in-small-cell-lung-cancer/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [EGFR Resisters and LCRF Research Partnership](https://egfrcancer.org/2021/11/12/egfr-resisters-and-lcrf-research-partnership/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [BLU-945 Clinical Trial Update: Travel Reimbursement for Both Patient and Caregiver](https://egfrcancer.org/2021/11/12/blu-945-clinical-trial-update-travel-reimbursement-for-both-patient-and-caregiver/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Advancing Person-Centered Care Through Innovation](https://egfrcancer.org/2021/11/12/advancing-person-centered-care-through-innovation/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Tonglen: An Ancient Eastern Compassion Meditation](https://egfrcancer.org/2021/11/12/tonglen-an-ancient-eastern-compassion-meditation/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs](https://egfrcancer.org/2021/11/12/scientists-learn-more-about-how-lung-cancer-becomes-resistant-to-drugs/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLC](https://egfrcancer.org/2021/11/12/new-mechanisms-under-study-to-overcome-osimertinib-resistance-in-egfr-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure](https://egfrcancer.org/2021/11/12/combination-atezolizumab-bevacizumab-pemetrexed-and-carboplatin-for-metastatic-egfr-mutated-nsclc-after-tki-failure/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Sintilimab Meets Primary End Point in ORIENT-31 Trial for EGFR+ Non-Squamous NSCLC](https://egfrcancer.org/2021/11/12/sintilimab-meets-primary-end-point-in-orient-31-trial-for-egfr-non-squamous-nsclc/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Uncommon EGFR Mutations Come Into Focus With Novel NSCLC Therapies](https://egfrcancer.org/2021/11/12/uncommon-egfr-mutations-come-into-focus-with-novel-nsclc-therapies/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation](https://egfrcancer.org/2021/11/12/stereotactic-body-radiotherapy-to-the-primary-lung-lesion-improves-the-survival-of-the-selected-patients-with-non-oligometastatic-nsclc-harboring-egfr-activating-mutation-with-first-line-egfr-tkis-a/) - Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
- [EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded!](https://egfrcancer.org/2021/12/07/egfr-resisters-and-lcrf-research-partnership-first-study-grant-awarded/) - Video: EGFR Resisters/LCRF research award recently granted to Yang Tian, entitled "Targeting lung lineage plasticity to suppress osimertinib-induced drug-tolerant persisters."
- [Third Annual EGFR Resisters Research Summit Overview](https://egfrcancer.org/2021/12/07/third-annual-egfr-resisters-research-summit-overview/) - Video: In November 2021, we held our 3rd Annual EGFR Resisters Research Summit for Young Investigators virtually. Hear brief summaries of the lung cancer presentation topics by Dr. Stephen Liu.
- [What Can you Expect from a Lung Cancer Clinical Trial](https://egfrcancer.org/2021/12/07/what-can-you-expect-from-a-lung-cancer-clinical-trial/) - Dr. Mark A. Socinski explains the process of participating in a lung cancer clinical trial from beginning to end.
- [Cracking the Code on Non-Small Cell Lung Cancer in Younger Adults](https://egfrcancer.org/2021/12/07/what-can-you-expect-from-a-lung-cancer-clinical-trial-2/) - A new study, Epidemiology of Young Lung Cancer (EoYLC), seeks to pinpoint risk factors that may lead to a lung cancer diagnosis in young people.
- [A Primer on EGFR TKIs and Their Resistance Mechanisms and Treatments](https://egfrcancer.org/2021/12/07/a-primer-on-egfr-tkis-and-their-resistance-mechanisms-and-treatments/) - This article details the different generations of TKIs, their modes of action and resistance mechanisms that develop as well as their treatments.
- [Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies](https://egfrcancer.org/2021/12/08/treating-disease-progression-with-osimertinib-in-egfr-mutated-non-small-cell-lung-cancer-novel-targeted-agents-and-combination-strategies/) - Post-osimertinib treatment options for EGFR-mutated NSCLC, providing an overview of ongoing clinical trials and proposing an algorithm to guide clinicians in managing progression.
- [Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC](https://egfrcancer.org/2021/12/08/overcoming-mechanisms-of-resistance-remains-at-the-forefront-for-egfr-mutant-nsclc/) - Although next-generation TKIs have helped to overcome resistance in EGFR lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance.
- [Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes](https://egfrcancer.org/2021/12/08/genomic-signatures-define-three-subtypes-of-egfr-mutant-stage-ii-iii-non-small-cell-lung-cancer-with-distinct-adjuvant-therapy-outcomes/) - This study demonstrates that predictive genomic signatures could potentially stratify resected EGFR-mutant NSCLC patients and provide precise guidance towards future personalized adjuvant therapy.
- [Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC](https://egfrcancer.org/2021/12/08/dr-brahmer-on-the-utility-of-consolidative-immunotherapy-vs-targeted-therapy-in-nsclc/) - Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.
- [EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC](https://egfrcancer.org/2021/12/08/egfr-combination-therapy-should-become-the-new-standard-first-line-treatment-in-advanced-egfr-mutant-nsclc/) - Recent data on combination strategies reveal the ability to delay the development of resistance and improve outcomes in advanced EGFR+ NSCLC patients.
- [Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study](https://egfrcancer.org/2021/12/08/sequential-afatinib-and-osimertinib-in-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-final-analysis-of-the-giotag-study/) - This study showed that afatinib followed by osimertinib treatment was effective in patients with NSCLC with EGFR mutations developing T790M resistance mutations on initial afatinib treatment.
- [Our New EGFR+ Lung Cancer Educational Resources](https://egfrcancer.org/2022/01/21/our-new-egfr-lung-cancer-educational-resources/) - The EGFR Resisters have created 5 fact sheets to help those with EGFR+ lung cancer and their caretakers to better understand their diagnosis and treatment options and ask the necessary questions.
- [New Clinical Trials](https://egfrcancer.org/2022/01/21/new-clinical-trials/) - New clinical trials for EGFR+ lung cancer patients that have progressed on TKIs.
- [Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary](https://egfrcancer.org/2022/01/21/comparing-egfr-tyrosine-kinase-inhibitor-treatments-in-egfr-mutated-non-small-cell-lung-cancer-across-asian-and-non-asian-patients-a-plain-language-summary/) - How people from different ethnic populations respond differently to TKI treatments for EGFR+ lung cancer.
- [Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective](https://egfrcancer.org/2022/03/16/iterative-upgrading-of-small-molecular-tyrosine-kinase-inhibitors-for-egfr-mutation-in-nsclc-necessity-and-perspective/) - This review focuses on: indications of approved small molecular kinase inhibitors for EGFR+ NSCLC; mechanisms of drug resistance and corresponding therapeutic strategies; principles of reasonable and precision molecular structure; and drug development discoveries of next-generation inhibitors for EGFR.
- [Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated NSCLC](https://egfrcancer.org/2022/03/16/patritumab-deruxtecan-granted-u-s-fda-breakthrough-therapy-designation-in-patients-with-metastatic-egfr-mutated-nsclc/)
- [Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC](https://egfrcancer.org/2022/03/16/daiichi-sankyo-astrazeneca-begin-phase-iii-trial-of-enhertu-in-her2-mutant-nsclc/) - The DESTINY-Lung04 trial is evaluating trastuzumab deruxtecan against standard-of-care platinum-pemetrexed doublet chemotherapy plus the checkpoint inhibitor pembrolizumab (Merck's Keytruda) in around 260 patients with unresectable, locally advanced, or metastatic NSCLC harboring HER2 exon 19 or 20 mutations.
- [Video: Clinical Trial Life Cycle](https://egfrcancer.org/2022/03/16/video-clinical-trial-life-cycle/) - Video: EGFR Resisters co-founders Jill Feldman"s and Ivy Elkins' presentation about the clinical trial life cycle.
- [Video: Who’s in? Who’s out? How Patients Are Selected for Clinical Trials](https://egfrcancer.org/2022/03/16/video-clinical-trial-life-cycle-2/) - Video: EGFR Resisters co-founder Jill Feldman discusses Who’s in? Who’s out? How Patients Are Selected for Clinical Trials with Dr. Jorge J Nieva of USC Norris Comprehensive Cancer Center.
- [Podcast: Breakthrough Therapies EGFR Mutant Lung Cancer with Zosia Piotrowska from IASLC](https://egfrcancer.org/2022/03/18/podcast-breakthrough-therapies-egfr-mutant-lung-cancer-with-zosia-piotrowska-from-iaslc/) - In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks with Dr. Zosia Piotrowska, Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital in Boston, Mass., about the current and future state of therapies for patients with EGFR mutant lung cancer
- [Experts Disagree on Adding Chemo to Targeted Drugs in EGFR+ NSCLC](https://egfrcancer.org/2022/03/18/experts-disagree-on-adding-chemo-to-targeted-drugs-in-egfr-nsclc/) - Two expert analyses arrive at opposite conclusions regarding the value for metastatic NSCLC of combining 1st generation EGFR TKIs with either chemotherapy or VEGF monoclonal antibodies.
- [Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients](https://egfrcancer.org/2022/03/18/single-cell-dna-seq-depicts-clonal-evolution-of-multiple-driver-alterations-in-osimertinib-resistant-patients/) - Distinct molecular driver alterations at osimertinib resistance coexist with initial EGFR mutations in single cancer cells.
- [Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence](https://egfrcancer.org/2022/03/18/uncommon-egfr-compound-mutations-in-non-small-cell-lung-cancer-nsclc-a-systematic-review-of-available-evidence/) - Compound EGFR mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations.
- [Osimertinib Shows Durable Results in Treating CNS Metastases in EGFR+ NSCLC](https://egfrcancer.org/2022/03/18/osimertinib-shows-durable-results-in-treating-cns-metastases-in-egfr-nsclc/) - Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from NSCLC in patients with certain mutations.
- [Research Articles on HER2 and Exon 20 Mutations in NSCLC](https://egfrcancer.org/2022/03/18/research-articles-on-her2-and-exon-20-mutations-in-nsclc/) - Read three research articles on HER2 and exon 20 mutations in non-small cell lung cancer.
- [Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers](https://egfrcancer.org/2022/03/18/detection-of-acquired-tert-amplification-in-addition-to-predisposing-p53-and-rb-pathways-alterations-in-egfr-mutant-lung-adenocarcinomas-transformed-into-small-cell-lung-cancers/) - Among the different mechanisms of acquired resistance to EGFR TKIs reported in EGFR+ NSCLC patients, histological transformation into SCLC occurs.
- [Slide Decks from the 2022 Targeted Therapies Meeting](https://egfrcancer.org/2022/03/18/slide-decks-from-the-2022-targeted-therapies-meeting/) - View the 2022 Targeted Therapies slide decks from the following presenters: Dr. Helena Yu, Dr. Katerina Politi, Dr. Noura Choudhury, Dr. Jonathan Riess, and Dr. Michael Grant.
- [Keeping Your Work Focused on Patients, Ivy Elkins, presenter](https://egfrcancer.org/2022/03/23/keeping-your-work-focused-on-patients-ivy-elkins-presenter/) - EGFR Resisters co-founder, Ivy Elkins speaks about the importance of including patient advocates in research throughout the life cycle of a project and suggested many ways patient advocates could help make both clinical and laboratory research more relevant and meaningful.
- [Synopsis Clinical Trial: Open for Enrollment](https://egfrcancer.org/2022/03/23/synopsis-clinical-trial-open-for-enrollment/) - This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked.
- [EGFR Resisters Grief and Coping Zoom Session with CancerCare Grief Counselor](https://egfrcancer.org/2022/03/23/egfr-resisters-grief-and-coping-zoom-session-with-cancercare-grief-counselor/) - This session on grief and lung cancer was recorded and is now available for on-demand viewing.
- [The Not Really Terminal Terminal Patient Put in the Wrong Terminal](https://egfrcancer.org/2022/03/23/the-not-really-terminal-terminal-patient-put-in-the-wrong-terminal/) - For patients who are diagnosed terminal and then don’t, um, terminate? That script is still in process. We’re dropped at the Terminal for the Terminal, but we don’t quite fit there.
- [INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance](https://egfrcancer.org/2022/06/29/insight-2-a-phase-ii-study-of-tepotinib-plus-osimertinib-in-met-amplified-nsclc-and-first-line-osimertinib-resistance/) - INSIGHT 2 is an ongoing study of effects and safety of tepotinib combined with osimertinib, in lung cancer patients with resistance mechanism of MET amplification.
- [EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation](https://egfrcancer.org/2022/06/29/egfr-advanced-nsclc-resistant-to-frontline-tkis-c797s-mutation/) - Experts discuss C797S resistance to frontline TKIs in EGFR+ lung cancer.
- [ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC](https://egfrcancer.org/2022/06/29/odac-recommends-new-trial-data-of-sintilimab-in-us-population-of-frontline-nsclc/) - The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous NSCLC.
- [Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus](https://egfrcancer.org/2022/06/29/distinct-genomic-profile-of-lung-cancer-in-never-smokers-comes-into-focus/) - A growing recognition of the distinct clinical, pathological, and biological features of lung cancers in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset.
- [Biomarkers in NSCLC](https://egfrcancer.org/2022/06/29/biomarkers-in-nsclc/) - In this video, Ivy Elkins and Rasheda Persinger discuss biomarker testing, treatments and symptoms with patients diagnosed with lung cancer.
- [I Don't Want to Survive, I Want to Live](https://egfrcancer.org/2022/06/29/i-dont-want-to-survive-i-want-to-live/) - In this video, EGFR Resisters co-founder Jill Feldman discusses that even though lung cancer survivors are living longer, survivorship care is commonly overlooked, and more palliative care and quality of life should be highly valued.
- [The end of my life was killing me](https://egfrcancer.org/2022/06/29/the-end-of-my-life-was-killing-me/) - Lung cancer survivor, Annabelle Gurwitch talks about her life after being diagnosed with a stage 4 diagnosis.
- [Overall Survival Not Extended With Bevacizumab and Erlotinib in EGFR-Mutant NSCLC](https://egfrcancer.org/2022/06/29/overall-survival-not-extended-with-bevacizumab-and-erlotinib-in-egfr-mutant-nsclc/) - Adding bevacizumab to erlotinib (Tarceva) in EGFR+ lung cancer patients did not prolong their survival, but both treatment arms with and without bevacizumab (Avastin) had relatively long survival durations.
- [Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing](https://egfrcancer.org/2022/06/29/lung-cancer-field-targets-immunotherapy-acquired-resistance-and-genomic-testing/) - Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for NSCLC and the current management of SCLC.
- [Dosing Begins in Phase 1/2 Study of Reqorsa Plus Osimertinib in Advanced NSCLC](https://egfrcancer.org/2022/06/29/dosing-begins-in-phase-1-2-study-of-reqorsa-plus-osimertinib-in-advanced-nsclc/) - Dosing has begun in patients with advanced NSCLC in the phase 1/2 Acclaim-1 clinical trial of quaratusugene ozeplasmid in combination with osimertinib after disease progression on osimertinib alone.
- [Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)](https://egfrcancer.org/2022/06/29/treatment-outcome-of-atypical-egfr-mutations-in-the-german-national-network-genomic-medicine-lung-cancer-nngm/) - In this retrospective, multicenter study of the national Network Genomic Medicine (nNGM) in Germany, 856 NSCLC cases with atypical EGFR mutations including co-occurring mutations were reported from 12 centers.
- [Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma](https://egfrcancer.org/2022/06/29/concurrent-tp53-mutations-facilitate-resistance-evolution-in-egfr-mutant-lung-adenocarcinoma/) - TP53 alterations associate with faster resistance evolution independent of mechanism in EGFR mutant NSCLC, and may cooperate with other genomic events to mediate acquisition of resistance mutations to EGFR TKIs.
- [Pivotal Trials Put HER2-Mutated NSCLC on Notice](https://egfrcancer.org/2022/06/29/pivotal-trials-put-her2-mutated-nsclc-on-notice/) - The R2D2 trial achieved a first by showing that HER2 mutations can be "treatable targets" in patients with previously treated, advanced HER2-mutated non-small cell lung cancer (NSCLC).
- [First Steps Down the HER3 Pathway in NSCLC Signal Early Success](https://egfrcancer.org/2022/06/29/first-steps-down-the-her3-pathway-in-nsclc-signal-early-success/) - HER3 expression has been identified as a favorable target. In December 2021 the FDA granted a breakthrough therapy designation to novel antibody-drug conjugate (ADC) patritumab deruxtecan.
- [A Phase I Study of Deferoxamine in People with Leptomeningeal Metastasis](https://egfrcancer.org/2022/06/29/first-steps-down-the-her3-pathway-in-nsclc-signal-early-success-2/) - The purpose of this study is to find the highest dose of deferoxamine that can be given safely in people with leptomeningeal metastases.
- [More Isn't Always Better: Understanding Cancer Treatment Tolerability](https://egfrcancer.org/2022/06/29/more-isnt-always-better-understanding-cancer-treatment-tolerability/) - Video: Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn't Always Better- Understanding Cancer Treatment Tolerability.
- [Making the Most of Time Between Scans](https://egfrcancer.org/2022/06/29/making-the-most-of-time-between-scans/) - There’s always a lot of discussion about scanxiety in the lung cancer community and managing your understandable anxiety leading up to these scans. How can we best handle the period of time between scans?
- [Maintaining Your Emotional Health While Caring for Others](https://egfrcancer.org/2022/06/29/maintaining-your-emotional-health-while-caring-for-others/) - Explore seven strategies to support your emotional health while caregiving.
- [Tipifarnib Prevents Emergence of Resistance to Osimertinib in EGFR+ NSCLC](https://egfrcancer.org/2022/06/29/tipifarnib-prevents-emergence-of-resistance-to-osimertinib-in-egfr-nsclc/) - Using a xenograft model and a PDX model of EGFRL858R/T790M lung cancer, co-treatment with tipifarnib prevented relapse to osimertinib for up to 6 months with no evidence of toxicity.
- [Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer](https://egfrcancer.org/2022/06/29/identification-of-optimal-dosing-schedules-of-dacomitinib-and-osimertinib-for-a-phase-i-ii-trial-in-advanced-egfr-mutant-non-small-cell-lung-cancer/) - Dacomitinib, a pan-HER inhibitor, is approved for first-line treatment and results in different acquired EGFR mutations than osimertinib that mediate on-target resistance. A combination of osimertinib and dacomitinib could induce more durable responses by preventing resistance.
- [Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer](https://egfrcancer.org/2022/06/29/identification-of-optimal-dosing-schedules-of-dacomitinib-and-osimertinib-for-a-phase-i-ii-trial-in-advanced-egfr-mutant-non-small-cell-lung-cancer-2/) - Using blood and tissue biopsies together can enrich finding a molecular alteration. Watch this video or read the transcript.
- [Is Lung Cancer Different in Non or Never-Smokers?](https://egfrcancer.org/2022/06/29/is-lung-cancer-different-in-non-or-never-smokers/) - Lung cancer in non-smokers is more common than many people realize. In fact, lung cancer in never-smokers is now considered the 6th most common cause of cancer deaths in the United States.
- [Future of Targeting EGFR Exon 20 Insertion Mutations in NSCLC](https://egfrcancer.org/2022/07/03/future-of-targeting-egfr-exon-20-insertion-mutations-in-nsclc/) - Dr. Joel Neal discusses novel therapy in EGFR exon 20 insertion–positive NSCLC and highlights ongoing clinical trials and the importance of biomarker testing.
- [EGFR Tyrosine Kinase Inhibitors and SCLC Transformation](https://egfrcancer.org/2022/07/03/egfr-tyrosine-kinase-inhibitors-and-sclc-transformation/) - In this video, Dr. Savi Salgia explains how treatment with a tyrosine kinase inhibitor (TKI) in patients with non–small cell lung cancer (NSCLC) can lead to disease transformation.
- [Drs. Christine Lovly and Helena Yu discuss and answer questions about their research projects funded by the EGFR Resisters](https://egfrcancer.org/2022/07/03/drs-christine-lovly-and-helena-yu-discuss-and-answer-questions-about-their-research-projects-funded-by-the-egfr-resisters/) - In this video, Dr. Upal Basu Roy from the LUNGevity Foundation conducts update discussions with Drs. Christine Lovly and Helena Yu their EGFR Resisters-funded research projects: persister cells and SCLC transformation.
- [FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics](https://egfrcancer.org/2022/07/03/fda-workshop-opportunities-to-improve-dose-optimization-designing-trials-and-applying-pharmacometrics/) - In this follow-on workshop, the FDA and ASCO will discuss research and clinical challenges for dose optimization and highlight strategies to improve dose optimization for anticancer agents.
- [Podcast: From the Patient's Eye View](https://egfrcancer.org/2022/07/03/podcast-from-the-patients-eye-view/) - In this podcast, Dann Wonser shares his own experience being diagnosed with lung cancer, by accident, in 2006. Dan’s story is inspirational, and he conveys his perspective of hope and fortitude as he continues to be active in his treatment.
- [When You Dread to Hear Your Results](https://egfrcancer.org/2022/07/03/when-you-dread-to-hear-your-results/) - How Juanita Segura, a lung cancer survivor, copes with her routine scans and scanxiety.
- [Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?](https://egfrcancer.org/2022/07/03/fear-of-cancer-recurrence-or-progression-what-is-it-and-what-can-we-do-about-it/) - Patients with cancer face a trajectory marked by emotional and physical distress that can be associated with both diagnosis and treatment. Fear of cancer recurrence or progression has been considered one of the most common unmet needs reported by patients diagnosed with both localized and metastatic disease.
- [Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management](https://egfrcancer.org/2022/07/03/third-generation-egfr-and-alk-inhibitors-mechanisms-of-resistance-and-management/) - Despite their efficacy, resistance to osimertinib and lorlatinib remains an unsolved fundamental challenge. Both ‘on-target’ mechanisms and ‘off-target’ mechanisms of resistance have been identified in patients with disease progression.
- [Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report](https://egfrcancer.org/2022/07/03/afatinib-for-the-treatment-of-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations-an-updated-database-of-1023-cases-brief-report/) - Afatinib should be considered as a 1st line treatment option for NSCLC patients with major uncommon, compound, ‘other’ (including E709X and L747X) and some specific exon 20 insertion mutations.
- [Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer](https://egfrcancer.org/2022/07/03/immunotherapy-based-combination-strategies-for-treatment-of-egfr-tki-resistant-non-small-cell-lung-cancer/) - In this review, the authors take stock of the relationship between EGFR mutations and PD-L1 expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC.
- [Fear or Survivor’s Guilt?](https://egfrcancer.org/2022/09/23/fear-or-survivors-guilt/) - When I hear the news that I lost a lung cancer sister or brother I’m not sure if I have survivor’s guilt or fear. Maybe a little of both!
- [2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC](https://egfrcancer.org/2022/09/23/2022-egfr-lung-cancer-rapid-recap-the-evolving-state-of-the-science-in-egfr-nsclc/) - This video provides a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting (ASCO), and offers expert insights into the shifting management landscape for metastatic EGFR+ NSCLC.
- [Duma Discusses the Unique Challenges of Women With Lung Cancer](https://egfrcancer.org/2022/09/24/duma-discusses-the-unique-challenges-of-women-with-lung-cancer/) - In these podcasts, Narjust Duma, MD, an assistant professor of medicine at Harvard Medical School, and physician and associate director of the Cancer Equity Program at Dana-Farber Cancer Institute, discusses lung cancer in women.
- [Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?](https://egfrcancer.org/2022/09/24/is-there-a-role-for-pd-l1-inhibitors-in-egfr-mutant-or-alk-rearranged-nsclc/) - John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements.
- [Dana Farber Webcast: Second Annual “Living with EGFR-Mutant Lung Cancer: A Virtual Forum for Patients and Caregivers”](https://egfrcancer.org/2022/09/24/dana-farber-webcast-second-annual-living-with-egfr-mutant-lung-cancer-a-virtual-forum-for-patients-and-caregivers/) - In this Dana Farber webcast, EGFR-mutant lung cancer, research advances, symptom management, as well as hearing from patients and caregivers were discussed.
- [Raising Kids While Battling Lung Cancer](https://egfrcancer.org/2022/09/24/raising-kids-while-battling-lung-cancer/) - In November of 2014 when I was diagnosed with lung cancer my daughter was 17 years old and a senior in high school. My two boys were 19 and 20 years old and had already graduated from high school and were in college.
- [Targeted Therapies Patient Forum 2022](https://egfrcancer.org/2022/09/24/targeted-therapies-patient-forum-2022/) - The 8th annual live patient forum where leading thoracic oncologists from around the world as well as lung cancer patients who are active within the patient advocacy community discuss subjects relevant to all targets, including breakout sessions on rare mutations.
- [Selecting Therapy for Advanced NSCLC With EGFR Mutations](https://egfrcancer.org/2022/09/24/selecting-therapy-for-advanced-nsclc-with-egfr-mutations/) - In this video presentation, a panel of lung cancer experts review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.
- [ASCO 2032: What Will Be the Big Story in Lung Cancer?](https://egfrcancer.org/2022/09/24/asco-2032-what-will-be-the-big-story-in-lung-cancer/) - Video: New clinical research unveiled at the recent ASCO annual meeting has the potential to significantly alter the treatment of lung cancer. But what will be the innovations we are talking about in 5 years? Or 10 years?
- [Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations](https://egfrcancer.org/2022/09/24/characteristics-of-and-treatment-strategies-for-advanced-egfr-mutant-nsclc-with-concomitant-braf-variations/) - BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear.
- [Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma](https://egfrcancer.org/2022/09/24/limited-benefit-from-the-addition-of-immunotherapy-to-chemotherapy-in-tki-refractory-egfr-mutant-lung-adenocarcinoma/) - Although it is known that anti-PD1/L1 monotherapy does not render significant benefit in patients with EGFR-mutant lung adenocarcinoma, whether the addition of anti-PD1/L1 therapy to chemotherapy can enhance chemotherapy efficacy for TKI-refractory EGFR-mutant lung adenocarcinoma patients is not clear.
- [EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC](https://egfrcancer.org/2022/09/24/egfr-tki-based-combos-could-lead-to-more-tailored-first-line-treatment-options-in-egfr-mutated-nsclc/) - Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.
- [Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation](https://egfrcancer.org/2022/09/24/meet-the-professor-current-and-future-management-of-non-small-cell-lung-cancer-with-an-egfr-mutation/) - In this video,
- [Not all EGFR Mutations Are the Same](https://egfrcancer.org/2022/09/24/not-all-egfr-mutations-are-the-same/) - First of all, EGFR stands for epidermal growth factor receptor, which is a protein found on the surface of cells in the body. EGFR is a normal part of the body’s functioning and helps cells grow and divide. When an EGFR mutation occurs, this means that there is an error in the gene that tells EGFR how to work.
- [How to Read Biomarker Test Results](https://egfrcancer.org/2022/09/24/how-to-read-biomarker-test-results/) - Biomarker testing is used among diagnosed patients with non-small cell lung cancer (NSCLC) to determine the presence of specific mutations or proteins associated with cancer.
- [#TogetherSeparately: Surviving Survivorship](https://egfrcancer.org/2022/09/24/togetherseparately-surviving-survivorship/) - Dr. Isabel Preeshagul was joined by Dr. Marleen Meyers and EGFR Resisters co-founder Jill Feldman for the LCRF Lung Cancer Community Talk.
- [What is Meant by “Informed Consent”?](https://egfrcancer.org/2022/09/24/what-is-meant-by-informed-consent/) - Unless you have participated in a clinical trial, you might not be familiar with the term “informed consent,” commonly used to refer to the document that patients are given when they are considering signing up for a trial.
- [Being Courageous Is A Real Choice](https://egfrcancer.org/2022/09/25/being-courageous-is-a-real-choice/) - There are moments I feel a great deal of fear and anxiety about the situations or choices when living with lung cancer. Sometimes I can overcome them but there are times it is hard.
- [FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer](https://egfrcancer.org/2022/09/25/fda-grants-accelerated-approval-to-fam-trastuzumab-deruxtecan-nxki-for-her2-mutant-non-small-cell-lung-cancer/) - On August 11, 2022, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER 2 NSCLC.
- [EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents](https://egfrcancer.org/2022/09/25/egfr-tyrosine-kinase-inhibitor-sequencing-revisited-from-the-revival-of-old-tools-to-the-integration-of-new-agents/) - Whether combination strategies will ultimately provide more prolonged OS to patients, as compared with sequential approaches, is a major question in the clinic.
- [WCLC (World Conference on Lung Cancer) 2022 Wrap Up](https://egfrcancer.org/2022/09/25/wclc-world-conference-on-lung-cancer-2022-wrap-up/) - Key highlights of the IASLC 2022 World Conference on Lung Cancer with Dr. Narjust Florez and Dr. Stephen Liu as they discuss the science, social engagement and notable abstracts with Dr. Ben Levy.
- [Survey: 77% of Women With Lung Cancer Report Sexual Dysfunction](https://egfrcancer.org/2022/09/25/survey-77-of-women-with-lung-cancer-report-sexual-dysfunction/) - A total of 77% of women with lung cancer surveyed reported moderate to severe sexual dysfunction, according to results of the SHAWL study presented at the World Conference on Lung Cancer.
- [Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations](https://egfrcancer.org/2022/09/25/dynamic-mutation-profiles-of-sclc-transformation-in-nsclc-patients-harboring-concurrent-egfr-tp53-rb1-mutations/) - Small cell lung cancer (SCLC) transformation remains one of the unsettled resistant mechanisms for lung adenocarcinoma (LUAD), of which co-occurring TP53 and RB1 mutations defined a subgroup of patients with increased risk of SCLC transformation.
- [Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC](https://egfrcancer.org/2022/09/25/dr-spira-on-the-further-investigations-of-lazertinib-amivantamab-in-egfr-mutant-nsclc/) - Since lazertinib/amivantamab has demonstrated the ability to overcome osimertinib resistance, investigators want to continue exploring optimal settings for the combination’s use.
- [Epidemiology of Young Lung Cancer Study](https://egfrcancer.org/2022/10/30/epidemiology-of-young-lung-cancer-study/) - This study seeks to help researchers and clinicians better understand why an increasing number of young people (under 50) are developing lung cancer.
- [Living With Lung Cancer](https://egfrcancer.org/2022/10/30/living-with-lung-cancer/) - What is it like living with lung cancer? Well for me it can be hell on earth at times. I go to sleep and wake up every day knowing I have lung cancer but have been making the most of it.
- [Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation](https://egfrcancer.org/2022/10/30/meet-the-professor-current-and-future-management-of-non-small-cell-lung-cancer-with-an-egfr-mutation-2/) - Lung cancer specialist Lecia V Sequist, MD, MPH discusses the current and future management of EGFR NSCLC with host Dr. Neal Love.
- [Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)](https://egfrcancer.org/2022/10/30/alternating-therapy-with-osimertinib-and-afatinib-for-treatment-naive-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-a-single-group-open-label-phase-2-trial-wjog10818l/) - Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial ((WJOG10818L).
- [Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC](https://egfrcancer.org/2022/10/30/locking-down-a-link-between-pollution-and-egfr-mutated-lung-nsclc/) - Fine particulate matter from the combustion of fossil fuels seemed to trigger NSCLC in never smokers through a process of "tumor promotion," according to a study on the etiology of EGFR+ disease.
- [Lower-Dose Trastuzumab Deruxtecan Shows Favorable Efficacy in HER2-Mutated NSCLC](https://egfrcancer.org/2022/10/30/lower-dose-trastuzumab-deruxtecan-shows-favorable-efficacy-in-her2-mutated-nsclc/) - Trastuzumab deruxtecan demonstrated clinically meaningful benefit and a favorable safety profile at the lower of 2 dose levels in patients with HER2 NSCLC, according to interim results of the DESTINY-Lung02 trial (NCT04644237) presented at ESMO 2022
- [Study of DZD9008 (WU-KONG6 Study) Meets Primary End Point of ORR in EGFR Exon20Ins-Positive NSCLC](https://egfrcancer.org/2022/10/30/study-of-dzd9008-wu-kong6-study-meets-primary-end-point-of-orr-in-egfr-exon20ins-positive-nsclc/) - Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of ORR and had a benign safety profile in EGFR EXON20 NSCLC.
- [Initial Analysis of INSIGHT 2: Tepotinib Plus Osimertinib Showed Promise in EGFR+ NSCLC that Progressed on 1st Line Osimertinib with MET Amplification](https://egfrcancer.org/2022/10/31/initial-analysis-of-insight-2-tepotinib-plus-osimertinib-showed-promise-in-egfr-nsclc-that-progressed-on-1st-line-osimertinib-with-met-amplification/) - Initial analysis of INSIGHT 2: Tepotinib plus osimertinib showed promise in EGFR+ NSCLC that progressed on osimertinib with MET amplification (from ESMO 2022).
- [Living Room Recap – Options and Next Steps If Your Lung Cancer Becomes Resistant to Your Course of Treatment](https://egfrcancer.org/2022/12/11/living-room-recap-options-and-next-steps-if-your-lung-cancer-becomes-resistant-to-your-course-of-treatment/) - What happens when your cancer becomes resistant to your course of treatment and progresses? That’s the question explored in this episode of our Lung Cancer Living Room series.
- [Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors](https://egfrcancer.org/2022/12/11/genomic-and-biological-study-of-fusion-genes-as-resistance-mechanisms-to-egfr-inhibitors/) - By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative resistance-causing fusion oncogene, we identify patients who benefit and those who do not from this treatment approach.
- [Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 3 of a 3-Part Series](https://egfrcancer.org/2022/12/11/meet-the-professor-current-and-future-management-of-non-small-cell-lung-cancer-with-an-egfr-mutation-part-3-of-a-3-part-series/) - Dr. Neil Love and Dr. Pasi Janne discuss the current and future management of EGFR+ NSCLC.
- [Challenges With and Strategies for Tissue Procurement in NSCLC](https://egfrcancer.org/2022/12/11/challenges-with-and-strategies-for-tissue-procurement-in-nsclc/) - Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.
- [Inroads to Targeting HER2-Mutant Lung Cancer Begin Taking Shape](https://egfrcancer.org/2022/12/11/inroads-to-targeting-her2-mutant-lung-cancer-begin-taking-shape/) - Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.
- [Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer](https://egfrcancer.org/2022/12/11/phase-ib-study-of-telisotuzumab-vedotin-in-combination-with-erlotinib-in-patients-with-c-met-protein-expressing-non-small-cell-lung-cancer/) - The results of a phase Ib study evaluating Teliso-V plus erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with c-Met-positive (+) NSCLC.
- [Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion](https://egfrcancer.org/2022/12/11/reviewing-evidence-for-therapies-in-nsclc-with-egfr-exon-20-insertion/) - Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with a NSCLC EGFR exon 20 insertion mutation.
- [The Current Landscape of Oncogene Targeted Therapies (ESMO and WCLC Recap)](https://egfrcancer.org/2022/12/11/the-current-landscape-of-oncogene-targeted-therapies-esmo-and-wclc-recap/) - ESMO and WCLC Recap: There was a focus on treating EGFR-positive NSCLC that has progressed after being treated with currently approved EGFR targeted therapies, with several presentations of new drug combinations and new EGFR targeted therapies.
- [Lung Cancer Research Foundation (LCRF) and EGFR Resisters Announce Research Awards](https://egfrcancer.org/2022/12/19/lung-cancer-research-foundation-lcrf-and-egfr-resisters-announce-research-awards/) - The EGFR Resisters are thrilled to announce the THREE 2022 grant recipients of our research award partnership with Lung Cancer Research Foundation.
- [Video Summary Recap: 2022 EGFR Resisters Research Summit](https://egfrcancer.org/2022/12/19/video-summary-recap-2022-egfr-resisters-research-summit/) - Video: Watch the recap of the 4th Annual 2022 EGFR Resisters Research Summit on November 17-18, 2022 in Chicago.
- [Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC](https://egfrcancer.org/2022/12/19/osimertinib-remains-the-preferred-frontline-choice-for-egfr-mutated-nsclc/) - Osimertinib (Tagrisso) remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer (NSCLC), says Zosia Piotrowska, MD, MHS.
- [The Future of Treating Oligometastatic Lung Cancer Is Personalized Care](https://egfrcancer.org/2022/12/19/the-future-of-treating-oligometastatic-lung-cancer-is-personalized-care/) - The tide has turned in lung cancer research, and with it, so must the paradigm on how to treat people with stage IV NSCLC.
- [HARMONIC Evaluates Novel Combination in Growing Population of Never Smokers With Advanced Lung Cancer](https://egfrcancer.org/2022/12/19/harmonic-evaluates-novel-combination-in-growing-population-of-never-smokers-with-advanced-lung-cancer/) - In combination with standard-of-care carboplatin and pemetrexed, the investigational agent LP-300 will be evaluated in never smokers with in the phase 2 HARMONIC study.
- [Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC](https://egfrcancer.org/2022/12/19/nadler-reviews-targeted-therapy-for-egfr-exon-20-insertion-nsclc/) - Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
- [Sunvozertinib Shows Activity and Tolerability in EGFR Exon 20+ NSCLC](https://egfrcancer.org/2022/12/19/sunvozertinib-shows-activity-and-tolerability-in-egfr-exon-20-nsclc/) - Sunvozertinib (DZD9008) has demonstrated activity in NSCLC harboring an EGFR exon 20 insertion mutation across mutation types and prior treatments, according to data pooled from 3 phase 1/2 clinical trials.
- [Thriving With Lung Cancer: What You Should Know About Care and Treatment](https://egfrcancer.org/2022/12/19/thriving-with-lung-cancer-what-you-should-know-about-care-and-treatment/) - What does it mean to thrive with lung cancer? Dr. Jyoti Patel discusses care and treatment goals, reviews current and emerging treatment options, and shares advice for living well and thriving with lung cancer.
- [Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification](https://egfrcancer.org/2022/12/19/tepotinib-and-gefitinib-show-long-os-in-egfr-nsclc-with-met-amplification/) - Tepotinib plus gefitinib led to improvements in progression-free survival and overall survival in patients with EGFR-mutant non–small cell lung cancer.
- [Amivantamab Combination Shows Efficacy Post-Osimertinib in EGFR+ NSCLC](https://egfrcancer.org/2022/12/19/amivantamab-combination-shows-efficacy-post-osimertinib-in-egfr-nsclc/) - Melina E. Marmarelis, MD, reports the rationale and key findings from the Chrysalis-2 trial of patients with EGFR-mutated advanced non–small cell lung cancer
- [Science Spotlight: NSCLC Transformation to SCLC](https://egfrcancer.org/2022/12/19/science-spotlight-nsclc-transformation-to-sclc/) - Video: Join lung cancer researcher Dr. Triparna Sen as she digs into what’s known about how EGFR+NSCLC cells transform into SCLC to escape targeted therapy treatment.
- [Making the Most of Time Between Scans](https://egfrcancer.org/2023/02/03/making-the-most-of-time-between-scans-2/) - How can we best handle the period of time between lung cancer scans?
- [Passing of The Baton—On the Death of Patient Research Advocates](https://egfrcancer.org/2023/02/03/passing-of-the-baton-on-the-death-of-patient-research-advocates/) - Unfortunately, longer survival doesn’t mean lung cancer patients are immune from death, and sadly our community has lost several prominent patient research advocates recently.
- [Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective Phase I study](https://egfrcancer.org/2023/02/03/safety-pharmacokinetic-and-clinical-activity-of-intrathecal-chemotherapy-with-pemetrexed-via-the-ommaya-reservoir-for-leptomeningeal-metastases-from-lung-adenocarcinoma-a-prospective-phase-i-study/) - This study aimed to evaluate the efficacy and toxicities of intrathecal chemotherapy with pemetrexed via Ommaya reservoir in LUAD with refractory leptomeningeal disease.
- [Making the Most of NSCLC Next-Generation Sequencing in the Real World](https://egfrcancer.org/2023/02/03/making-the-most-of-nsclc-next-generation-sequencing-in-the-real-world/) - Newly diagnosed patients with NSCLC benefit tremendously from next-generation sequencing (NGS) to test for driver mutations and determine the best first-line treatment.
- [Emerging Role of Antibody-Drug Conjugates in the Management of Non-Small Cell Lung Cancer](https://egfrcancer.org/2023/02/03/emerging-role-of-antibody-drug-conjugates-in-the-management-of-non-small-cell-lung-cancer/) - This webinar on the emerging role of antibody-drug conjugates (ADCs) features perspectives from Drs Alexander Spira and Helena Yu.
- [The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study](https://egfrcancer.org/2023/02/03/the-role-of-chemotherapy-plus-immune-checkpoint-inhibitors-in-oncogenic-driven-nsclc-a-university-of-california-lung-cancer-consortium-retrospective-study/) - There is a paof data on ICIs plus doublet chemotherapy in patients with advanced NSCLC with actionable mutations. We sought to provide insight into the role of this combination.
- [Newer Targets in NSCLC Lead to Directed Therapies](https://egfrcancer.org/2023/02/03/newer-targets-in-nsclc-lead-to-directed-therapies/) - This article covers treatment updates on EGFR Exon 20, MET exon 14 skipping, and HER2 mutations.
- [Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report](https://egfrcancer.org/2023/02/03/unexpected-cardiotoxicity-in-patients-with-her2-mutant-nsclc-treated-with-trastuzumab-deruxtecan-a-case-report/) - We report the first two cases of drug-related cardiotoxicity with acute myocarditis that developed after the first trastuzumab deruxtecan cycle.
- [New Treatment Options for Stage IV NSCLC With Driver Alterations](https://egfrcancer.org/2023/02/03/new-treatment-options-for-stage-iv-nsclc-with-driver-alterations/) - The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies -- DESTINY-Lung01 and CodeBreaK100 -- incorporated into the guidance.
- [Antibody-drug conjugates in lung cancer: dawn of a new era?](https://egfrcancer.org/2023/02/03/antibody-drug-conjugates-in-lung-cancer-dawn-of-a-new-era/) - ADCs are now joining the list as potential options for lung cancer patients.
- [Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022](https://egfrcancer.org/2023/02/06/spira-highlights-key-advancements-across-the-nsclc-treatment-paradigm-in-2022/) - Dr. Spira highlighted the top advancements across NSCLC in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.
- [Is There a Unicorn Among the Uncommon EGFR Mutations?](https://egfrcancer.org/2023/02/06/is-there-a-unicorn-among-the-uncommon-egfr-mutations/) - Unlike the “classical” mutations comprising EGFR exon 19 deletions and exon 21 L858R substitution mutations which are well studied in landmark trials, the optimal treatment strategy for these uncommon mutations remains uncertain.
- [Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study](https://egfrcancer.org/2023/02/06/osimertinib-in-non-small-cell-lung-cancer-nsclc-with-atypical-egfr-activating-mutations-a-retrospective-multicenter-study/) - This multicenter retrospective study evaluates the efficacy of osimertinib among patients with NSCLC harboring atypical EGFR mutations.
- [Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789](https://egfrcancer.org/2023/08/05/merck-provides-update-on-phase-3-trials-keynote-641-and-keynote-789-2/) - Merck announced that the Phase 3 KEYNOTE-789 trial evaluating KEYTRUDA in combination with pemetrexed plus platinum-based chemotherapy did not meet its dual primary endpoint of OS for the treatment of patients with metastatic nonsquamous NSCLC, with epidermal growth factor receptor (EGFR)-genomic tumor mutations, who have previously progressed on a tyrosine kinase inhibitor (TKI), including osimertinib.
- [Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity](https://egfrcancer.org/2023/08/05/resistance-to-egfr-inhibitors-fitness-competition-and-diversity/) - There is still a lot to be learned regarding resistance mechanisms in EGFR-mutant NSCLC, especially when osimertinib is used in the first-line setting and especially in the category of pathway indifference resistance cancers.
- [Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors](https://egfrcancer.org/2023/08/05/trastuzumab-deruxtecan-meets-orr-end-point-in-her2-expressing-advanced-solid-tumors/) - The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) met the prespecified target for objective response rate (ORR) and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial (NCT04482309).
- [Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer](https://egfrcancer.org/2023/08/05/candidate-mechanisms-of-acquired-resistance-to-first-line-osimertinib-in-egfr-mutated-advanced-non-small-cell-lung-cancer/) - This analysis identifies acquired resistance mechanisms to first-line osimertinib.
- [Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations](https://egfrcancer.org/2023/08/05/experts-debate-tki-use-after-disease-progression-for-patients-with-egfr-mutations/) - Upon disease progression, some clinicians suggest that continued TKI use in conjunction with chemotherapy is the optimal strategy for patient care. Others contend there is a lack of conclusive evidence to recommend this approach.
- [Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expression Breast Cancer](https://egfrcancer.org/2023/08/05/patritumab-deruxtecan-continues-to-generate-responses-in-previously-treated-egfr-mutated-nsclc-and-her3-expression-breast-cancer/) - The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer (NSCLC), according to updated data from a phase 1 trial (NCT03260491).
- [Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial](https://egfrcancer.org/2023/08/05/nitroglycerin-plus-whole-intracranial-radiation-therapy-for-brain-metastases-in-patients-with-non-small-cell-lung-cancer-a-randomized-open-label-phase-2-clinical-trial/) - The concurrent administration of NTG and radiation therapy improves iORR and ICPFS among patients with NSCLC with BM. The benefit in ICPFS is significant in the EGFRm patient subgroup.
- [Perspectives in Lung Cancer Care: Targeted Therapies 101](https://egfrcancer.org/2023/09/28/perspectives-in-lung-cancer-care-targeted-therapies-101/) - Latest information on Targeted Therapies for NSCLC
- [Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study](https://egfrcancer.org/2023/09/28/nitroglycerin-plus-whole-intracranial-radiation-therapy-for-brain-metastases-in-patients-with-non-small-cell-lung-cancer-a-randomized-open-label-phase-2-clinical-trial-2/) - The efficacy and safety of lazertinib were recapitulated in a real-world study reflecting routine clinical practice in Korea, showing durable disease control both systematically and intracranially, with manageable side effects.
- [What to Know About Biomarker Testing for Lung Cancer: An Expert Q&A](https://egfrcancer.org/2023/09/28/what-to-know-about-biomarker-testing-for-lung-cancer-an-expert-qa/) - Identifying specific biomarkers of a tumor is important because some mutations, particularly in lung cancer, can be "drivers" of the cancer, a primary cause of that cancer growing and dividing.
- [PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion](https://egfrcancer.org/2023/09/28/pten-loss-expands-the-histopathologic-diversity-and-lineage-plasticity-of-lung-cancers-initiated-by-rb1-trp53-deletion/) - These results identify PTEN loss as a clinically relevant genetic alteration driving the molecular and histopathologic heterogeneity of neuroendocrine lung tumors initiated by Rb1/Trp53 mutations.
- [Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions](https://egfrcancer.org/2023/09/28/minimal-residual-disease-monitoring-in-radically-treated-non-small-cell-lung-cancer-challenges-and-future-directions/) - Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors.
- [Lung adenocarcinoma promotion by air pollutants](https://egfrcancer.org/2023/09/28/lung-adenocarcinoma-promotion-by-air-pollutants/) - Here we propose that environmental particulate matter measuring ≤2.5 μm (PM2.5), known to be associated with lung cancer risk, promotes lung cancer by acting on cells that harbour pre-existing oncogenic mutations in healthy lung tissue.
- [Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations](https://egfrcancer.org/2023/09/28/efficacy-of-osimertinib-in-patients-with-lung-cancer-positive-for-uncommon-egfr-exon-19-deletion-mutations/) - The uncommon EGFR exon 19 deletion , L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models.
- [Facebook Live: EGFR Resisters and LUNGevity Research Partnership Update](https://egfrcancer.org/2023/09/28/facebook-live-egfr-resisters-and-lungevity-research-partnership-update/) - Dr. Christine Lovly, Dr. Helena Yu, Jill Feldman, and Ivy Elkins join Dr. Upal Basu-Roy discuss advancements in research in EGFR lung cancer: Persister cells, sclc transformation, and personal cancer vaccines on the horizon.
- [The Promise of Precision Medicine, Targeted Therapies & Immunotherapy: The Next Wave!](https://egfrcancer.org/2023/09/28/the-promise-of-precision-medicine-targeted-therapies-immunotherapy-the-next-wave/) - The Lung Cancer Living Room featured Joel W. Neal, MD, PhD, of the Stanford Cancer Institute discussing the next wave of precision medicine and its impact on lung cancer patients.
- [Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress](https://egfrcancer.org/2023/09/28/antibody-drug-conjugates-for-lung-cancer-payloads-and-progress/) - Traztuzumab deruxtecan (T-DXd) is the first antibody-drug conjugate (ADC) approved for lung cancer in patients with HER2 mutation–positive NSCLC demonstrated in the DESTINY-Lung01 and DESTINY-Lung02 trials.
- [Osimertinib and Chemotherapy Improves PFS in Advanced EGFRm NSCLC](https://egfrcancer.org/2023/09/28/osimertinib-and-chemotherapy-improves-pfs-in-advanced-egfrm-nsclc/) - The combination of osimertinib (Tagrisso) with chemotherapy generated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs osimertinib alone for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC., according to results from the phase 3 FLAURA2 trial (NCT04035486).1
- [Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab with and without Atezolizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked](https://egfrcancer.org/2023/09/28/phase-ii-randomized-trial-of-carboplatin-pemetrexed-and-bevacizumab-with-and-without-atezolizumab-in-stage-iv-non-squamous-non-small-cell-lung-cancer-patients-who-harbor-a-sensitizing-egfr-mutation/) - This phase II trial is evaluating a strategy of adding atezolizumab to carboplatin, pemetrexed, and bevacizumab to determine if this regimen can improve outcomes in patients with stage IV non-squamous NSCLC who either have never smoked or have tumors with sensitizing EGFR mutations.
- [Clinical Updates for the Management of Lung Cancer Brain Metastases](https://egfrcancer.org/2023/09/29/clinical-updates-for-the-management-of-lung-cancer-brain-metastases/) - As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.
- [Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC](https://egfrcancer.org/2023/09/29/long-term-benefit-of-amivantamab-continues-in-postplatinum-nsclc/) - Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate clinical benefit for amivantamabvmjw (Rybrevant), according to findings presented at the European Lung Cancer Congress 2023 .
- [Research Update: EGFR Resisters + LCRF](https://egfrcancer.org/2023/09/29/research-update-egfr-resisters-lcrf/) - The EGFR Resisters Grant was awarded in 2021 to Yang Tian, PhD, Icahn School of Medicine at Mount Sinai. Dr. Tian does her work focused on understanding and overcoming resistance to osimertinib.
- [Pembro Plus Chemo Fails to Show Efficacy Benefit in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC (KEYNOTE-789)](https://egfrcancer.org/2023/09/29/pembro-plus-chemo-fails-to-show-efficacy-benefit-in-tki-resistant-egfr-mutated-metastatic-nonsquamous-nsclc-keynote-789/) - An analysis from the randomized, phase 3 KEYNOTE-789 trial did not show a significant efficacy benefit with the addition of pembrolizumab to chemotherapy in patients with tyrosine kinase inhibitor (TKI)-resistant, EGFR+ metastatic NSCLC.
- [Updates in EGFR-Mutated Oligometastatic NSCLC](https://egfrcancer.org/2023/09/29/updates-in-egfr-mutated-oligometastatic-nsclc/) - Study finds survival boost, while experts weigh in on RT in local consolidative therapy and more
- [Advocating, Accelerating, and Amplifying Lung Cancer Discovery: Lung-MAP Advocacy Webinar Replay](https://egfrcancer.org/2023/09/29/advocating-accelerating-and-amplifying-lung-cancer-discovery-lung-map-advocacy-webinar-replay/) - This webinar features leading experts from the current Lung-MAP clinical trial to discuss recent trial updates, challenges to the traditional clinical trial landscape that Lung-MAP is working to overcome, and opportunities for patient engagement in the process.
- [Learning to Reframe Empowers Me as I Live With Chronic Cancer](https://egfrcancer.org/2023/09/29/learning-to-reframe-empowers-me-as-i-live-with-chronic-cancer/) - After being diagnosed with an incurable cancer, I had to reframe my thinking to focus on the positive.
- [Continued Emergence of Targeted Therapies for EGFR-Mutant NSCLC Underscores Importance of Molecular Testing](https://egfrcancer.org/2023/09/29/continued-emergence-of-targeted-therapies-for-egfr-mutant-nsclc-underscores-importance-of-molecular-testing/) - Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.
- [Targeted Therapies in Lung Cancer Patient Forum](https://egfrcancer.org/2023/09/29/targeted-therapies-in-lung-cancer-patient-forum/) - Watch this targeted therapies presentation on post-osimertinb/Tagrisso treatments. It's very informative
- [Amivantamab/Lazertinib is a Potential Chemo-Free Option in EGFR-Mutated NSCLC](https://egfrcancer.org/2023/09/29/amivantamab-lazertinib-is-a-potential-chemo-free-option-in-egfr-mutated-nsclc/) - The phase 1/1b CHRYSALIS trial demonstrated activity: overall response rate of 61% and a median progression-free survival of 12.2 months compared with 14% and 4.2 months for patients with NSCLC with low MET expression.
- [Rezivertinib Generates Promising CNS Efficacy in NSCLC With an EGFR T790M Mutation](https://egfrcancer.org/2023/09/29/rezivertinib-generates-promising-cns-efficacy-in-nsclc-with-an-egfr-t790m-mutation/) - Individual data from 2 studies evaluating rezivertinib in patients with advanced NSCLC harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.
- [2023 ASCO: Highlights of Lung Cancer Research](https://egfrcancer.org/2023/09/29/2023-asco-highlights-of-lung-cancer-research/) - The biggest lung cancer news to be presented at this year's meeting was the final 5-year survival results of the ADAURA trial.
- [Existing drug shows promise treating most prevalent type of lung cancer](https://egfrcancer.org/2023/09/29/existing-drug-shows-promise-treating-most-prevalent-type-of-lung-cancer/) - The study shows that the FDA-approved medication crizotinib (also known as Xalkori) is effective at inhibiting the growth of non-small cell lung cancer with the most common genetic mutations.
- [Patients with Brain Metastases Deserve Better—A Hard-Won Perspective](https://egfrcancer.org/2023/09/29/patients-with-brain-metastases-deserve-better-a-hard-won-perspective/) - Here, I hope to convince you that we should be prioritizing cancer research, specifically lung cancer research involving brain metastases.
- [Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting](https://egfrcancer.org/2023/09/29/zipalertinib-in-egfr-exon-20-mutant-non-small-cell-lung-cancer-drug-development-in-a-rare-but-crowded-setting/) - In the article that accompanies this editorial, Piotrowska et al discuss results from a phase I/II study of zipalertinib, an irreversible, oral EGFR TKI in patients with recurrent or metastatic NSCLC with EGFR ex20ins mutations.
- [Clinician Spotlight: Paul Stockhammer, MD, PhD](https://egfrcancer.org/2023/09/29/clinician-spotlight-paul-stockhammer-md-phd/) - As a third-year resident at Yale School of Medicine last year, Dr Stockhammer received the Distinguished Young Investigator Research Award at the 2022 EGFR Research Summit for his work entitles “Co-occurring Alterations in Multiple Tumor Suppressor Genes Associate with Outcomes in Patients with EGFR-mutant Lung Cancer.”
- [Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR+ NSCLC after Disease Progression on Osimertinib](https://egfrcancer.org/2023/09/29/phase-3-mariposa-2-study-meets-dual-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybrevant-amivantamab-vmjw-pl/) - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating RYBREVANT® (amivantamab-vmjw) given with and without lazertinib, combined with chemotherapy (carboplatin and pemetrexed) versus chemotherapy alone.
- [Want to Learn More About Clinical Trials and Trial Design?](https://egfrcancer.org/2023/09/29/want-to-learn-more-about-clinical-trials-and-trial-design/) - Lung Cancer Living Room™ gathered experts to discuss and demystify the subject of clinical trials for lung cancer.
- [Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis](https://egfrcancer.org/2023/09/29/genomic-alterations-and-the-incidence-of-brain-metastases-in-advanced-and-metastatic-nsclc-a-systematic-review-and-meta-analysis/) - Identifying genomic alterations associated with BM development could influence screening and determine targeted treatmen
- [ADCs Offer Exciting Potential in Lung Cancer](https://egfrcancer.org/2023/09/29/adcs-offer-exciting-potential-in-lung-cancer/) - Antibody-drug conjugates (ADC) represent one of the most exciting areas of ongoing development for the treatment of patients with NSCLC and SCLC.
- [Podcast: An Introduction to Molecular Testing](https://egfrcancer.org/2023/09/29/podcast-an-introduction-to-molecular-testing/) - In this podcast, experts come together to provide an introduction to molecular testing.
- [FDA Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC](https://egfrcancer.org/2023/09/29/fda-approval-sought-for-amivantamab-plus-chemo-in-egfr-exon-20-insertion-nsclc/) - A supplemental biologics license application (sBLA) seeking the expanded approval of amivantamab-vmjw (Rybrevant) in combination with carboplatin plus pemetrexed for use in the frontline treatment for metastatic EGFR exon 20 NSCLC has been submitted to the FDA.
- [New EGFR Resisters Branded Hoodies, Sweatshirts, Colors, and Slogans!](https://egfrcancer.org/2023/09/29/new-egfr-resisters-branded-hoodies-sweatshirts-colors-and-slogans/) - The EGFR Resisters has established our new Branded Sales Website stocked with EGFR Resisters Tshirts, sweatshirts, and hoodies. A percentage of each sale will go directly to our EGFR Resisters/LUNGevity research fund.
- [EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists](https://egfrcancer.org/2023/12/24/egfr-mutations-are-not-all-the-same-the-importance-of-biomarker-testing-in-non-small-cell-lung-cancer-nsclc-a-podcast-discussion-between-patients-and-oncologists/) - The objective of this podcast is to explain the importance of biomarker testing for patients with EGFR-mutated non-small cell lung cancer.
- [Clinician Spotlight: Dr. Josh Reuss](https://egfrcancer.org/2023/12/24/clinician-spotlight-dr-josh-reuss/) - Dr. Josh Reuss, is Assistant Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center Washington, DC and participated in the EGFR Resisters Research .
- [Scanxiety: Tips from a Survivor and Expert](https://egfrcancer.org/2023/12/24/scanxiety-tips-from-a-survivor-and-expert/) - “Scanxiety” is a term that people with cancer use to describe the anxiousness and fear they experience before, during, and after scans to diagnose cancer, monitor treatment progress, or to determine whether it has or hasn’t recurred.
- [Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC](https://egfrcancer.org/2023/12/24/novel-antibody-drug-conjugate-shows-efficacy-in-advanced-egfr-mutated-nsclc/) - Treatment with patritumab deruxtecan (HER3-DXd) after progression with an EGFR TKI and platinum-based chemotherapy resulted in "clinically meaningful and durable efficacy" in patients with advanced EGFR+ NSCLC, according to the phase II HERTHENA-Lung01 trial.
- [Studies Indicate Progress, Highlight Challenges of Combating Lung Cancer Stigma](https://egfrcancer.org/2023/12/24/studies-indicate-progress-highlight-challenges-of-combating-lung-cancer-stigma/) - Incredible advancements in lung cancer research and treatment have been reported during the 2023 World Conference on Lung Cancer, but the stigma surrounding lung cancer remains a deadly problem.
- [Zongertinib Demonstrates Clinical Activity in HER2-Mutant Solid Tumors](https://egfrcancer.org/2023/12/24/zongertinib-demonstrates-clinical-activity-in-her2-mutant-solid-tumors/) - In patients with HER2–mutant non–small cell lung cancer (NSCLC) treated in a cohort of the phase 1a/b BEAMION Lung-1 trial (NCT04886804), treatment with zongertinib (BI 1810631) showed preliminary efficacy signals and acceptable, according to results of the the dose-escalation portion of the study.
- [Data From FLAURA2: Osimertinib With or Without Chemotherapy in Metastatic NSCLC](https://egfrcancer.org/2023/12/24/data-from-flaura2-osimertinib-with-or-without-chemotherapy-in-metastatic-nsclc/) - Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer.
- [Are New NSCLC Findings Practice Changing, or Is PFS Boost Not Enough?](https://egfrcancer.org/2023/12/24/are-new-nsclc-findings-practice-changing-or-is-pfs-boost-not-enough/) - Drs, H, Jack West, Devika Das, and Charu Aggarwal weigh in on the implications of the FLAURA2 trial results.
- [Making a Case for Second-Line TKI in EGFR-Mutated NSCLC](https://egfrcancer.org/2023/12/24/making-a-case-for-second-line-tki-in-egfr-mutated-nsclc/) - Is continuing osimertinib ideal in 2nd and 3rd line settings in EGFR+ NSCLC?
- [Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer](https://egfrcancer.org/2023/12/24/landmark-phase-3-mariposa-study-meets-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybrevant-amivantamab-vmjw/) - The pivotal Phase 3 MARIPOSA study met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients receiving RYBREVANT® plus lazertinib compared to osimertinib.
- [Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award](https://egfrcancer.org/2023/12/24/drs-susumu-kobayashi-and-alexandre-reuben-announced-as-recipients-of-egfr-resisters-lungevity-research-award/) - This collaboration aims to fund research with the potential to transform the outcomes for patients diagnosed with EGFR-positive lung cancer by ultimately changing EGFR-positive lung cancer into a chronic or curable condition.
- [Clinician Spotlight: Dr. Christine Bestvina](https://egfrcancer.org/2023/12/24/clinician-spotlight-dr-christine-bestvina/) - I was motivated to pursue lung cancer research because of the opportunity to push forward where we are in the clinic, and a desire to offer patients not just better treatments in the future, but potentially better treatments today depending on clinical trials.
- [Sometimes I Feel Frustrated](https://egfrcancer.org/2023/12/24/sometimes-i-feel-frustrated/) - Living with lung cancer is rough. Many look at me and tell me, “Juanita, you look so good,” or “You look so well.” But they don’t know what I’m going through mentally.
- [New Options Challenge Standard Treatments in EGFR-Mutant NSCLC (MARIPOSA and MARIPOSA-2 Trials)](https://egfrcancer.org/2023/12/24/new-options-challenge-standard-treatments-in-egfr-mutant-nsclc-mariposa-and-mariposa-2-trials/) - Two positive phase III trials involving amivantamab (Rybrevant)-based regimens introduced new first- and second-line options in EGFR+ NSCLC, though toxicity with the combination strategies raised some concerns.
- [Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases](https://egfrcancer.org/2023/12/24/osimertinib-plus-chemo-improves-cns-pfs-in-egfr-advanced-nsclc-with-baseline-brain-metastases/) - Osimertinib plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR+NSCLC who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.
- [EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy (PAPILLON Trial)](https://egfrcancer.org/2023/12/24/egfr-exon-20-insertion-nsclc-population-sees-pfs-benefit-from-amivantamab-chemotherapy-papillon-trial/) - Amivantamab in combination with chemotherapy showed significantly improved PFS and a higher response rate compared to chemotherapy alone in treatment-naive patients with advanced EGFR exon 20 insertions NSCLC, demonstrating its efficacy as a first-line treatment.
- [Trastuzumab Deruxtecan Wins EU Approval for HER2-Mutated Advanced NSCLC (DESTINY-Lung02 trial)](https://egfrcancer.org/2023/12/24/trastuzumab-deruxtecan-wins-eu-approval-for-her2-mutated-advanced-nsclc-destiny-lung02-trial/) - The EC has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with advanced NSCLC whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
- [A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)](https://egfrcancer.org/2023/12/24/a-phase-3-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-mutated-in-non-small-cell-lung-cancer-attlas-kcsg-lu19-04/) - This randomized, open-label, multicenter, phase 3 study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel and carboplatin (ABCP) in EGFR or ALK-mutated NSCLC that progressed prior to TKI therapy.
- [Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC](https://egfrcancer.org/2023/12/27/dato-dxd-significantly-improves-pfs-in-select-subsets-of-advanced-metastatic-nsclc/) - The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.
- [Current Treatment Landscape for EGFR-Mutated NSCLC](https://egfrcancer.org/2023/12/27/current-treatment-landscape-for-egfr-mutated-nsclc/) - Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR+ NSCLC after progression on TKIs and platinum-based chemotherapy.
- [EGFR Resisters 5th Annual Research Summit Wrap Up](https://egfrcancer.org/2023/12/27/egfr-resisters-5th-annual-research-summit-wrap-up/) - Earlier this month, 15 young EGFR lung cancer investigators from the U.S., along with a panel of expert mentor judges and patient advocates, gathered together for our 5th annual EGFR Resisters Research Summit.
- [Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2](https://egfrcancer.org/2023/12/27/patient-perspective-patients-with-egfr-nsclc-may-still-opt-for-quality-over-quantity-after-flaura2/) - Patients want improved efficacy, but not necessarily at the expense of their quality of life. Combination treatment comes with increased toxicities.
- [Ask the Experts Webinar: Clinical Trials within Uncommon EGFR Alterations in NSCLC](https://egfrcancer.org/2023/12/27/ask-the-experts-webinar-clinical-trials-within-uncommon-egfr-alterations-in-nsclc/) - This educational webinar featuring oncology experts and patient advocates discusses the therapeutic landscape of uncommon EGFR alterations within NSCLC as well as current clinical trials aimed at advancing therapeutic options in this space.
- [Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC](https://egfrcancer.org/2023/12/27/halmos-highlights-evaluation-of-the-egfr-inhibitor-bdtx-1535-in-nsclc/) - Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
- [Clinician Spotlight: Dr. Elaine Shum](https://egfrcancer.org/2023/12/27/clinician-spotlight-dr-elaine-shum/) - I have been interested in oncology research since I was a high school student when I worked in a laboratory focused on oncolytic viruses.
- [Frontline Combinations Better Survival Rates in EGFRm Lung Cancer](https://egfrcancer.org/2023/12/27/frontline-combinations-better-survival-rates-in-egfrm-lung-cancer/) - Julia Rotow, MD, discussed emerging data on upfront therapies for patients with lung cancer harboring EGFR mutations in a presentation at the 18th Annual New York Lung Cancers Symposium.
- [Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC](https://egfrcancer.org/2023/12/27/osimertinib-with-or-without-chemotherapy-in-egfr-mutated-advanced-nsclc/) - First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR+ advanced NSCLC.
- [Current Landscape and the New Emerging Therapies in EGFR-positive NSCLC](https://egfrcancer.org/2023/12/27/current-landscape-and-the-new-emerging-therapies-in-egfr-positive-nsclc/) - This video presentation includes lung cancer experts and EGFR Resisters co-founder Jill Feldman discussing the treatment options after osimertinib (Tagrisso) failure.
- [Discussing Biomarkers and Best Options in NSCLC](https://egfrcancer.org/2023/12/27/discussing-biomarkers-and-best-options-in-nsclc/) - In this video, lung cancer expert Dr. Hossein Borghaei provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium.
- [Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results](https://egfrcancer.org/2023/12/27/interim-management-strategies-could-aid-patients-with-advanced-nsclc-awaiting-biomarker-test-results/) - Although biomarker testing is crucial for determining optimal targeted therapies for patients with advanced NSCLC, the time between conducting these tests and receiving results poses challenges for both oncologists and patients.

## Pages

- [Home](https://egfrcancer.org/) - We are a grassroots, patient-driven community, dedicated exclusively to changing EGFR positive lung cancer into a manageable, chronic disease. Email: info@egfrcancer.org
- [Membership](https://egfrcancer.org/egfr-resisters-membership/) - Meet our EGFR Resisters members. Join today! EGFR positive lung cancer are lung cancers testing positive for an EGFR mutation...
- [2026 EGFR Resisters Patient and Caregiver Summit - Sponsors](https://egfrcancer.org/2026-egfr-resisters-patient-and-caregiver-summit-sponsor-reg/) - This form is for individuals interested in attending EGFR Resisters Patient and Caregiver Summit from August 14th – 16th, 2026 in Rosemont, Illinois.
- [Newsletter Archives](https://egfrcancer.org/newsletter-archives/) - Stay up to date with EGFR Resisters lung cancer news and updates!
- [Monthly Newsletters](https://egfrcancer.org/egfr-monthly-newsletters/)
- [Leadership](https://egfrcancer.org/egfr-resisters-leadership/) - Meet the EGFR Resisters team. We are a non-profit dedicated to EGFR lung cancer & our grassroots patient-driven community.
- [2026 EGFR Resisters Patient and Caregiver Summit](https://egfrcancer.org/2026-egfr-resisters-patient-and-caregiver-summit/) - This form is for individuals interested in attending EGFR Resisters Patient and Caregiver Summit from August 14th – 16th, 2026 in Rosemont, Illinois.
- [accessibility](https://egfrcancer.org/accessibility/)
- [Contact Us](https://egfrcancer.org/contact-egfr-resisters/) - Contact the EGFR Resisters: advocacy group for EGFR positive lung cancer patients, family and caregivers. Email: info@egfrcancer.org
- [EGFR Resisters Patient & Caregiver Summit](https://egfrcancer.org/egfr-resisters-patient-caregiver-summit/) - View the 2025 EGFR Resisters Patient & Caregiver Summit session videos.
- [Support](https://egfrcancer.org/support/) - Join our community today! Fight EGFR lung cancer by donating, joining our community and fundraising! Email: info@egfrcancer.org
- [Policies](https://egfrcancer.org/policies/)
- [Opt-out preferences](https://egfrcancer.org/opt-out-preferences/)
- [Privacy Statement (US)](https://egfrcancer.org/privacy-statement-us/)
- [Imprint](https://egfrcancer.org/imprint/)
- [Biomarker Groups](https://egfrcancer.org/biomarker-groups-2/) - EGFR positive lung cancer are lung cancers testing positive for an EGFR mutation for which there are treatments to directly target the lung cancer cells.
- [Lung Cancer Advocacy](https://egfrcancer.org/lung-cancer-advocacy/) - EGFR positive lung cancer are lung cancers testing positive for an EGFR mutation for which there are treatments to directly target the lung cancer cells.
- [About EGFR](https://egfrcancer.org/about-egfr/) - EGFR positive lung cancer are lung cancers testing positive for an EGFR mutation for which there are treatments to directly target the lung cancer cells.
- [Join EGFR](https://egfrcancer.org/join-egfr/) - The strength of our membership will drive and fund novel EGFR lung cancer research and clinical trials. Join us today!
- [WHEN EGFR+ LUNG CANCER SPREADS TO THE BRAIN](https://egfrcancer.org/a-discussion-with-duke/) - Laura Alder, MD and Trey Mulliken, MD will lead a comprehensive discussion regarding the identification and treatment for these conditions.
- [Instagram](https://egfrcancer.org/instagram/)
- [Twitter](https://egfrcancer.org/twitter/)
- [Research Awards](https://egfrcancer.org/research-awards/)
- [Annual Research Summit](https://egfrcancer.org/annual-research-summit/) - An academic research summit focusing on the advancement of EGFRm treatment paradigms through meaningful collaboration between physician scientists.
- [EDUCATION](https://egfrcancer.org/ask-the-egfr-experts/) - EGFR lung cancer education including videos and downloadable fact sheets. Webinar series highlighting experts in the field of EGFR lung cancer. We'd like to thank Blueprint Medicine for sponsoring the webinar series on Progression and Resistance for the EGFR Resisters community.
- [EGFR Resisters on YouTube](https://egfrcancer.org/egfr-videos/) - EGFR Resisters Youtube channel videos.
- [Welcome and Newsletter Signup](https://egfrcancer.org/egfr-welcome-newsletters-signup/)
- [Young Investigators](https://egfrcancer.org/young-investigators/) - Research conducted by medical and graduate students, postdoctoral and clinical fellows, and residents. Many go on to very successful careers in biomedical research.
- [Project Priority](https://egfrcancer.org/project-priority/) - To empower the EGFR Resisters community to have an impact on treatment development and future research. The Patient Reported Initiative On Resistance, Incidence, Treatment studY (Project PRIORITY) is a patient-founded and patient-driven research partnership between the EGFR Resisters and LUNGevity Foundation.
- [Our Mission](https://egfrcancer.org/our-mission/) - EGFR Resisters aim to improve EGFR positive lung cancer outcomes, change this into a manageable disease, and continue research to raise awareness of EGFR+ lung cancer and to address critical and clinical research gaps.
- [Expert Partnerships](https://egfrcancer.org/expert-partnerships/) - EGFR Resisters Medical Advisors: Lung cancers that test positive for an EGFR mutation. EGFR stands for epidermal growth factor receptor. Join our grassroots patient-driven community.
- [Alliances & Resources](https://egfrcancer.org/resources/) - Valuable resources offering support, clinical trial information, and inspiration for those living with and/or impacted by EGFR positive lung cancer.
- [Disclaimer](https://egfrcancer.org/disclaimer/) - Medical disclaimer for egfrcancer.org
- [Facebook](https://egfrcancer.org/facebook/)
- [ADVOCACY](https://egfrcancer.org/news/advocacy/) - The latest EGFR positive lung cancer news and research. Learn more!
- [COPING & STORIES](https://egfrcancer.org/news/coping-stories/) - The latest EGFR positive lung cancer news and research. Learn more!
- [RESEARCH & TREATMENT](https://egfrcancer.org/news/research-treatment/) - The latest EGFR positive lung cancer news and research. Learn more!
- [News](https://egfrcancer.org/news/) - The latest EGFR positive lung cancer news and research. Learn more!

## Feeds

- [Instagram](https://egfrcancer.org/fts/my-feed/)
- [YouTube](https://egfrcancer.org/fts/my-feed-3/)

## Categories

- [Stories](https://egfrcancer.org/category/stories/)
- [Resources](https://egfrcancer.org/category/resources/)
- [Treatments](https://egfrcancer.org/category/treatments/)
- [Partners](https://egfrcancer.org/category/partners/)
- [Funding](https://egfrcancer.org/category/funding/)
- [Advocacy](https://egfrcancer.org/category/advocacy/)
- [Research](https://egfrcancer.org/category/research/)
- [Coping With Cancer](https://egfrcancer.org/category/coping-with-cancer/)
- [EGFR Resisters Announcements/Updates](https://egfrcancer.org/category/egfr-resisters-announcements-updates/)